Becton, Dickinson and (BDX) 10-K 24 Nov 21 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Sep. 30, 2021	Oct. 31, 2021	Mar. 31, 2021
Entity Information [Line Items]
Document type	10-K
Document Annual Report	true
Document period end date	Sep. 30, 2021
Current fiscal year end date	--09-30
Document Transition Report	false
Entity File Number	001-4802
Entity registrant name	BECTON, DICKINSON AND COMPANY
Entity central index key	0000010795
Document fiscal year focus	2021
Document fiscal period focus	FY
Amendment flag	false
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-0760120
Entity Address, Address Line One	1 Becton Drive,
Entity Address, City or Town	Franklin Lakes,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07417-1880
City Area Code	201
Local Phone Number	847-6800
Entity well-known seasoned issuer	Yes
Entity voluntary filers	No
Entity Current Reporting Status	Yes
Entity current reporting status	Yes
Entity filer category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
ICFR Auditor Attestation Flag	true
Entity shell company	false
Entity public float			$ 70,616,222,365
Entity common stock, shares outstanding (shares)		284,023,582
Common Stock  Issued at Par Value | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, par value $1.00
Trading Symbol	BDX
Security Exchange Name	NYSE
Depositary shares [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B
Trading Symbol	BDXB
Security Exchange Name	NYSE
1.000% Notes due December 15, 2022 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due December 15, 2022
Trading Symbol	BDX22A
Security Exchange Name	NYSE
1.900% Notes due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.900% Notes due December 15, 2026
Trading Symbol	BDX26
Security Exchange Name	NYSE
1.401% Notes due May 24, 2023 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.401% Notes due May 24, 2023
Trading Symbol	BDX23A
Security Exchange Name	NYSE
3.020% Notes due May 24, 2025 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	3.020% Notes due May 24, 2025
Trading Symbol	BDX25
Security Exchange Name	NYSE
0.632% Notes due June 4, 2023 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.632% Notes due June 4, 2023
Trading Symbol	BDX/23A
Security Exchange Name	NYSE
1.208% Notes due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.208% Notes due June 4, 2026
Trading Symbol	BDX/26A
Security Exchange Name	NYSE
Notes 1.213% due February 12, 2036 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.213% Notes due February 12, 2036
Trading Symbol	BDX/36
Security Exchange Name	NYSE
Notes 0.000% due August 13, 2023 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.000% Notes due August 13, 2023
Trading Symbol	BDX23B
Security Exchange Name	NYSE
Notes 0.034% due August 13, 2025 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.034% Notes due August 13, 2025
Trading Symbol	BDX25A
Security Exchange Name	NYSE

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 20,248	$ 17,117	$ 17,290
Cost of products sold	10,821	9,540	9,002
Selling and administrative expense	4,867	4,325	4,332
Research and development expense	1,339	1,096	1,062
Acquisitions and other restructurings	185	309	480
Other operating expense, net	238	363	654
Total Operating Costs and Expenses	17,449	15,633	15,530
Operating Income	2,799	1,484	1,760
Interest expense	(469)	(528)	(639)
Interest income	9	7	12
Other (expense) income, net	(97)	23	43
Income Before Income Taxes	2,242	985	1,176
Income tax provision (benefit)	150	111	(57)
Net Income	2,092	874	1,233
Preferred stock dividends	(90)	(107)	(152)
Net income applicable to common shareholders	$ 2,002	$ 767	$ 1,082
Earnings Per Share, Basic [Abstract]
Earnings Per Share, Basic	$ 6.92	$ 2.75	$ 4.01
Earnings Per Share, Diluted [Abstract]
Diluted Earnings per Share (USD per share)	$ 6.85	$ 2.71	$ 3.94

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net Income	$ 2,092	$ 874	$ 1,233
Other Comprehensive Income (Loss), Net of Tax
Foreign currency translation adjustments	124	(161)	(93)
Defined benefit pension and postretirement plans	255	(35)	(275)
Cash flow hedges	81	(67)	(6)
Other Comprehensive Income (Loss), Net of Tax	460	(265)	(374)
Comprehensive Income	$ 2,552	$ 609	$ 859

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Current Assets
Cash and equivalents	$ 2,283	$ 2,825
Restricted cash	109	92
Short-term investments	12	20
Trade receivables, net	2,497	2,398
Inventories	2,866	2,743
Prepaid expenses and other	1,072	891
Total Current Assets	8,838	8,969
Property, Plant and Equipment, Net	6,393	5,923
Goodwill	23,901	23,620
Developed Technology, Net	9,417	10,146
Customer Relationships, Net	2,818	3,107
Other Intangibles, Net	548	560
Other Assets	1,952	1,687
Total Assets	53,866	54,012
Current Liabilities
Short-term debt	500	707
Accounts payable	1,793	1,355
Accrued expenses	2,943	2,638
Salaries, wages and related items	1,214	993
Income taxes	176	144
Total Current Liabilities	6,626	5,836
Long-Term Debt	17,110	17,224
Long-Term Employee Benefit Obligations	1,228	1,435
Deferred Income Taxes and Other Liabilities	5,225	5,753
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Preferred stock	2	2
Common stock — $1 par value: authorized — 640,000,000 shares; issued — 364,639,901 shares in 2021 and 2020.	365	365
Capital in excess of par value	19,272	19,270
Retained earnings	13,826	12,791
Deferred compensation	23	23
Common stock in treasury — at cost — 80,163,949 shares in 2021 and 74,622,657 shares in 2020.	(7,723)	(6,138)
Accumulated other comprehensive loss	(2,088)	(2,548)
Total Shareholders’ Equity	23,677	23,765
Total Liabilities and Shareholders’ Equity	$ 53,866	$ 54,012
Common stock, par value (USD per share)	$ 1	$ 1
Common stock, shares authorized (shares)	640,000,000	640,000,000
Common stock, shares issued (shares)	364,639,901	364,639,901

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
Statement of Financial Position [Abstract]
Common stock, par value (USD per share)	$ 1	$ 1
Common stock, shares authorized (shares)	640,000,000	640,000,000
Common stock, shares issued (shares)	364,639,901	364,639,901
Common stock in treasury, shares (shares)	80,163,949	74,622,657

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Operating Activities
Net Income	$ 2,092	$ 874	$ 1,233
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization	2,273	2,154	2,253
Share-based compensation	237	244	261
Deferred income taxes	(304)	(302)	(381)
Change in operating assets and liabilities:
Trade receivables, net	(95)	(48)	(51)
Inventories	(104)	(125)	(149)
Prepaid expenses and other	(186)	81	299
Accounts payable, income taxes and other liabilities	687	205	(470)
Pension obligation	71	95	(123)
Excess tax benefits from payments under share-based compensation plans	15	52	55
Gain on sale of business	0	0	(336)
Product liability-related charges	361	378	914
Other, net	(400)	(68)	(177)
Net Cash Provided by Operating Activities	4,647	3,539	3,330
Investing Activities
Capital expenditures	(1,231)	(810)	(957)
Acquisitions, net of cash acquired	(508)	(164)	0
Proceeds from divestitures, net	0	0	477
Other, net	(142)	(257)	(261)
Net Cash Used for Investing Activities	(1,880)	(1,232)	(741)
Financing Activities
Change in credit facility borrowings	0	(485)	485
Proceeds from long-term debt and term loans	4,869	3,389	2,224
Payments of debt and term loans	(5,112)	(4,664)	(4,744)
Proceeds from issuance of equity securities	0	2,917	0
Repurchase of common stock	(1,750)	0	0
Dividends paid	(1,048)	(1,026)	(984)
Other, net	(265)	(109)	(205)
Net Cash (Used for) Provided by Financing Activities	(3,306)	22	(3,223)
Effect of exchange rate changes on cash and equivalents and restricted cash	15	(3)	(12)
Net (Decrease) Increase in Cash and Equivalents and Restricted Cash	(525)	2,326	(646)
Opening Cash and Equivalents and Restricted Cash	2,917	590	1,236
Closing Cash and Equivalents and Restricted Cash	$ 2,392	$ 2,917	$ 590

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the "Company" or "BD") have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30. Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities. Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters assumed in the acquisition of C.R. Bard, Inc. ("Bard"), which are further discussed in Note 5. Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of expected credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four one Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill which arise from acquisitions of businesses. The Company currently reviews goodwill for impairment using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units generally represent one level below reporting segments. The Company’s review of goodwill for each reporting unit compares the fair value of the reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2021 indicated that all identified reporting units’ fair values exceeded their respective carrying values. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss). Revenue Recognition The Company recognizes revenue from product sales when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized upon customer acceptance of these installed products. Revenue for certain service arrangements, including extended warranty and software maintenance contracts, is recognized ratably over the contract term. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. Variable consideration such as rebates, sales discounts and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices, and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Equipment lease transactions with customers are evaluated and classified as either operating or sales-type leases. Generally, these arrangements are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period defined within the customer agreement. Additional disclosures regarding the Company's accounting for revenue recognition are provided in Note 6. Shipping and Handling Costs The Company considers its shipping and handling costs to be contract fulfillment costs and records them within Selling and administrative expense. Shipping expense was $656 million, $551 million and $511 million in 2021, 2020 and 2019, respectively. Contingencies The Company establishes accruals for future losses which are both probable and can be reasonably estimated (and in the case of environmental matters, without considering possible third-party recoveries). Additional disclosures regarding the Company's accounting for contingencies are provided in Note 5. Derivative Financial Instruments All derivatives are recorded in the balance sheet at fair value and changes in fair value are recognized currently in earnings unless specific hedge accounting criteria are met. Any deferred gains or losses associated with derivative instruments are recognized in income in the period in which the underlying hedged transaction is recognized. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows for all other derivatives, including undesignated hedges, are classified in the same line item as the cash flows of the related hedged item, which is generally within operating or financing activities. Additional disclosures regarding the Company's accounting for derivative instruments are provided in Note 13. Income Taxes The Company has reviewed its needs in the United States for possible repatriation of undistributed earnings of its foreign subsidiaries and continues to invest foreign subsidiaries earnings outside of the United States to fund foreign investments or meet foreign working capital and property, plant and equipment expenditure needs. As a result, the Company is permanently reinvested with respect to all of its historical foreign earnings as of September 30, 2021. Deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is not practicable because of the complexities associated with its hypothetical calculation. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. Additional disclosures regarding the Company's accounting for income taxes are provided in Note 16. Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation. Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Notes 9 and 14. Level 1 — Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2 — Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 — Inputs to the valuation methodology which are unobservable and significant to the fair value measurement. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates. BD’s Intention to Spin Off Diabetes Care On May 6, 2021, the Company announced its intention to spin off its Diabetes Care business as a separate publicly traded company to BD’s shareholders. The proposed spin-off is intended to be a tax-free transaction for U.S. federal income tax purposes and is expected to be completed in the first half of calendar year 2022, subject to the satisfaction of customary conditions

Accounting Changes

Accounting Changes	12 Months Ended
	Sep. 30, 2021
Accounting Changes and Error Corrections [Abstract]
Accounting Standards Update and Change in Accounting Principle	Accounting Changes New Accounting Principles Adopted In June 2016, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company’s adoption of this accounting standard on October 1, 2020, using the modified retrospective method, did not have a material impact on the Company's consolidated financial statements. On October 1, 2020, the Company retrospectively adopted an accounting standard update which added, removed and clarified disclosure requirements relating to defined benefit plans and other postretirement plans. The Company’s adoption of this update on October 1, 2020 did not materially impact its disclosures. See Note 9 for the Company’s defined pension plan and other benefit plan disclosures. In July 2018, the FASB issued accounting standard update (“ASU”) ASU 2018-09, "Codification Improvements", which, among other items, amended an illustrative example of a fair value hierarchy disclosure to indicate that a certain type of investment should not always be considered to be eligible to use the net asset value ("NAV") per share practical expedient. Also, it further clarified that an entity should evaluate whether a readily determinable fair value exists or whether its investments qualify for the NAV practical expedient. The Company early adopted this standard in the fourth quarter of fiscal year 2020 on a prospective basis, which is reflected in the fair value hierarchy classification of pension assets in Note 9, but does not change the fair value measurements of the investments. In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The Company early adopted this standard as of April 1, 2020 on a prospective basis. The adoption of this standard did not materially impact the Company's consolidated financial statements. In February 2016, the FASB issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019, and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 17. On October 1, 2018, the Company adopted Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") using the modified retrospective method. Under ASC 606, revenue is recognized upon the transfer of control of goods or services to customers and reflects the amount of consideration to which a reporting entity expects to be entitled in exchange for those goods or services. The Company assessed the impact of this new standard on its consolidated financial statements based upon a review of contracts that were not completed as of October 1, 2018. This accounting standard adoption, which is further discussed in Note 6, did not materially impact any line items of the Company's consolidated income statements and balance sheet. On October 1, 2018, the Company retrospectively adopted an accounting standard update which requires all components of net periodic pension and postretirement benefit costs to be disaggregated from the service cost component and to be presented on the income statement outside a subtotal of income from operations, if one is presented. Upon the Company's adoption of the accounting standard update, which did not have a material impact on its consolidated financial statements, all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other (expense) income, net on its consolidated income statements for all periods presented. On October 1, 2018, the Company adopted an accounting standard update which requires that the income tax effects of intercompany sales or transfers of assets, except those involving inventory, be recognized in the income statement as income tax expense (or benefit) in the period that the sale or transfer occurs. The Company adopted this accounting standard update, which did not have a material impact on its consolidated financial statements, using the modified retrospective method.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity Changes in certain components of shareholders’ equity were as follows: Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2018 $ 347 $ 16,179 $ 12,596 $ 22 (78,463) $ (6,243) Net income — — 1,233 — — — Cash dividends: Common ($3.08 per share) — — (832) — — — Preferred — — (152) — — — Common stock issued for share-based compensation and other plans, net — (170) (1) 1 2,155 53 Share-based compensation — 261 — — — — Common stock held in trusts, net (a) — — — — 48 — Effect of change in accounting principle (see Note 2) — — 68 — — — Balance at September 30, 2019 $ 347 $ 16,270 $ 12,913 $ 23 (76,260) $ (6,190) Net income — — 874 — — — Cash dividends: Common ($3.16 per share) — — (888) — — — Preferred — — (107) — — — Common stock issued for: Preferred shares converted to common shares 12 (9) — — — — Public equity offerings 6 2,909 — — — — Share-based compensation and other plans, net — (143) — — 1,597 52 Share-based compensation — 244 — — — — Common stock held in trusts, net (a) — — — — 41 — Balance at September 30, 2020 $ 365 $ 19,270 $ 12,791 $ 23 (74,623) $ (6,138) Net income — — 2,092 — — — Cash dividends: Common ($3.32 per share) — — (958) — — — Preferred — — (90) — — — Common stock issued for share-based compensation and other plans, net — (85) — — 1,068 15 Share-based compensation — 237 — — — — Common stock held in trusts, net (a) — — — — 33 — Repurchase of common stock — (150) — — (6,643) (1,600) Effect of change in accounting principle (see Note 2) — — (9) — — — Balance at September 30, 2021 $ 365 $ 19,272 $ 13,826 $ 23 (80,164) $ (7,723) (a) Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. Share Repurchases In fiscal year 2021, the Company executed two accelerated share repurchase agreements and accounted for each agreement as two transactions upon prepayment: (1) the initial delivery of shares was recorded as an increase to Common stock in treasury to recognize the acquisition of common stock acquired in a treasury stock transaction, and (2) the remaining amount of shares was recorded as a decrease to Capital in excess of par value to recognize a net share-settled forward sale contract indexed to the Company's own common stock. The impacts of these accelerated share repurchase transactions were as follows: Execution Date Settlement Date Aggregate Common Stock Repurchased (millions of dollars) Initial Shares Delivered (in thousands) Additional Shares Delivered at Settlement (in thousands) (a) Total Shares Delivered (in thousands) Q3 2021 Q4 2021 $ 500 1,658 403 2,062 Q4 2021 Q1 2022 750 2,515 462 2,977 (a) Upon final settlement of each repurchase agreement and the forward sale contract, the Company’s receipt of additional shares was recorded as an increase to Common stock in treasury and an offsetting increase to Capital in excess of par value . The final settlement for the fourth quarter transaction amounted to $150 million. The Company also repurchased approximately 2.066 million shares of its common stock during fiscal year 2021 through open market repurchases, which were recorded as a $500 million increase to Common stock in treasury . The share repurchases discussed above were made pursuant to the repurchase program authorized by the Board of Directors on September 24, 2013 for 10 million shares, for which there is no expiration date. In November 2021, the Board of Directors authorized the Company to repurchase up to an additional 10 million shares of BD common stock, for which there is no expiration date. Common and Preferred Stock Conversions and Offerings In accordance with their terms, the Company's 2.475 million mandatory convertible preferred shares that were issued in May 2017 in connection with the Company's acquisition of Bard were converted into 11.703 million shares of BD common stock on the mandatory conversion date of May 1, 2020. Also in May 2020, the Company completed registered public offerings of equity securities including: • 6.250 million shares of the Company's common stock for net proceeds of $1.459 billion (gross proceeds of $1.500 billion). • 1.500 million shares of the Company's mandatory convertible preferred stock (ownership is held in the form of depositary shares, each representing a 1/20th interest in a share of preferred stock) for net proceeds of $1.459 billion (gross proceeds of $1.500 billion). If and when declared, dividends on the mandatory convertible preferred stock will be payable on a cumulative basis at an annual rate of 6.00% on the liquidation preference of $1,000 per preferred share ($50 per depositary share). The shares of preferred stock are convertible to a minimum of 5.2 million and up to a maximum of 6.2 million shares of Company common stock at an exchange ratio, based on the market price of the Company’s common stock at the date of conversion, and no later than the mandatory conversion date of June 1, 2023. The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Benefit Plans Cash Flow Balance at September 30, 2018 $ (1,909) $ (1,162) $ (729) $ (17) Other comprehensive loss before reclassifications, net of taxes (427) (93) (325) (9) Amounts reclassified into income, net of 52 — 49 3 Balance at September 30, 2019 $ (2,283) $ (1,256) $ (1,005) $ (23) Other comprehensive loss before reclassifications, net of taxes (338) (161) (101) (76) Amounts reclassified into income, net of 74 — 66 8 Balance at September 30, 2020 $ (2,548) $ (1,416) $ (1,040) $ (91) Other comprehensive income before reclassifications, net of taxes 383 124 187 72 Amounts reclassified into income, net of 77 — 68 9 Balance at September 30, 2021 $ (2,088) $ (1,292) $ (784) $ (10) The amount of foreign currency translation recognized in other comprehensive income during the years ended September 30, 2021, 2020 and 2019 included net gains (losses) relating to net investment hedges, as further discussed in Note 13. Other comprehensive income relating to benefit plans during the year ended September 30, 2021 included a net gain of $24 million recognized as a result of the Company’s remeasurement, as of October 31, 2020, of the legacy Bard U.S. defined pension benefit plan upon its merger with the BD defined benefit cash balance pension plan in the first quarter of fiscal year 2021. The amounts recognized in other comprehensive income relating to cash flow hedges in 2021 and 2020 related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note 13. The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows: (Millions of dollars) 2021 2020 2019 Benefit Plans Income tax (provision) benefit for net gains (losses) recorded in other comprehensive income $ (42) $ 30 $ 91 The tax impacts for cash flow hedges recognized in other comprehensive income before reclassifications in 2021, 2020 and 2019 were immaterial to the Company's consolidated financial results. The tax impacts for reclassifications out of Accumulated other comprehensive income (loss) relating to benefit plans and cash flow hedges in 2021, 2020 and 2019 were also immaterial to the Company's consolidated financial results.

Earnings per Share

Earnings per Share	12 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2021 2020 2019 Average common shares outstanding 289,288 278,971 269,943 Dilutive share equivalents from share-based plans (a) (b) 2,801 3,431 4,832 Average common and common equivalent shares outstanding — assuming dilution 292,089 282,402 274,775 (a) In 2021, 2020 and 2019, dilutive share equivalents associated with mandatory convertible preferred stock of 6 million, 9 million and 12 million, respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. The issuance of the convertible preferred stock is further discussed in Note 3. (b) In both 2021 and 2020, 1 million of certain share-based compensation awards were excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares. In 2019, no such awards were excluded from the diluted earnings per share calculation. Additional disclosures regarding the Company’s share-based compensation are provided in Note 8.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments The Company has certain future purchase commitments entered in the normal course of business to meet operational and capital requirements. As of September 30, 2021, these commitments aggregated to approximately $1.670 billion and will be expended over the next several years. Contingencies Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation in which the Company is a party. With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to the civil investigative demands (“CIDs”) served by the Department of Justice, discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows. Product Liability Matters The Company believes that certain settlements and judgments, as well as legal defense costs, may be covered under indemnification obligations from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability indemnification arrangements may be less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that other parties will pay claims or that indemnity will be otherwise available. Hernia Product Claims As of September 30, 2021, the Company is defending approximately 25,030 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court and in a federal multi-district litigation (“MDL”) established in the Southern District of Ohio, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. The first bellwether trial in the hernia MDL began in August 2021, resulting in a complete defense verdict. Trials are scheduled into fiscal year 2022 in various state and/or federal courts, including one trial currently scheduled for January 2022 in the MDL. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. Women’s Health Product Claims As of September 30, 2021, the Company is defending approximately 405 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 830 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue. The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. In July 2015, the Company reached an agreement with Medtronic in which Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic toward these potential settlements. As of September 30, 2021, the Company has paid Medtronic $161 million toward these potential settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products. As of September 30, 2021, the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,295 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ($33 million compensatory; $35 million punitive). In March 2021, the Appellate Division of the New Jersey Superior Court vacated the verdict and ordered a new trial. Plaintiffs have sought appeal of the reversal to the New Jersey Supreme Court and the Company has cross-appealed on a separate issue; the court has advised it will consider the appeal and cross-appeal. Additional trials of Women’s Health Product Claims may take place over the next 12 months, which could potentially include consolidated trials. During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Filter Product Claims As of September 30, 2021, the Company is defending approximately 275 product liability claims involving the Company’s line of inferior vena cava (“IVC”) filters (collectively, the “Filter Product Claims”). The majority of those claims were previously pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims either have been, or are in the process of being, remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun. Federal and state court trials are scheduled over the next 12 months. As of September 30, 2021, the Company entered into settlement agreements and/or settlement agreements in principle for approximately 9,505 cases. In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. Other Legal Matters The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. On February 27, 2020, a putative class action captioned Kabak v. Becton, Dickinson and Company, et al., Civ. No. 2:20-cv-02155 (SRC) (CLW), now captioned Industriens Pensionsforsikring v. Becton, Dickinson and Company, et al., was filed in the U.S. District Court for the District of New Jersey against the Company and certain of its officers. The complaint, which purports to be brought on behalf of all persons (other than defendants) who purchased or otherwise acquired the Company's common stock from November 5, 2019 through February 5, 2020, asserts claims for purported violations of Sections 10 and 20 of the Securities Exchange Act of 1934 and Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder, and seeks, among other things, damages and costs. The complaint alleges that defendants concealed material information regarding Alaris TM infusion pumps, including that (1) certain pumps exhibited software errors, (2) the Company was investing in remediation efforts as opposed to other enhancements and (3) the Company was thus reasonably likely to recall certain pumps and/or experience regulatory delays. These alleged omissions, the complaint asserts, rendered certain public statements about the Company’s business, operations and prospects false or misleading, causing investors to purchase stock at an inflated price. The plaintiff filed a second amended complaint to add certain additional factual allegations on February 3, 2021, which the Company moved to dismiss on March 19, 2021. The motion to dismiss was granted and the second amended complaint was dismissed in its entirety on September 15, 2021. The court’s order, however, gave plaintiff forty-five days to replead, which it did on October 29, 2021. The Company believes the allegations are without merit and intends to defend itself vigorously. On November 2, 2020, a civil action captioned Jankowski v. Forlenza, et al., Civ. No. 2:20-cv-15474, was filed in the U.S. District Court for the District of New Jersey by a shareholder, Ronald Jankowski, derivatively on behalf of the Company, against its individual directors and certain of its officers. The complaint seeks recovery for breach of fiduciary duties by directors and various officers; violations of the Securities Exchange Act of 1934; and insider trading. In general, the complaint alleges, among other things, that various directors and/or officers (1) caused the Company to issue purportedly misleading statements and SEC filings regarding Alaris TM infusion pumps, (2) issued a misleading proxy statement, (3) engaged in improper insider trading and (4) caused or contributed to various violations of the Securities Exchange Act of 1934, including sections 10(b), 14(a) and 21D. The complaint seeks damages, including restitution and disgorgement of profits, and an injunction requiring the Company to undertake remedial measures with respect to certain corporate governance and internal procedures. A second derivative action, Schranz v. Polen, et al., Civ. No 2:21-cv-01081, was filed on January 24, 2021 in the U.S. District Court for the District of New Jersey and the two actions were consolidated. In March 2021, the Company received letters from two additional shareholders which, in general, mirrored the allegations in the Jankowski and Schranz consolidated actions, and demanded, among other things, that the Board of Directors pursue civil action against members of management for claimed breaches of fiduciary duties. Consistent with New Jersey law, the Board appointed a special committee to review the allegations and demands in the derivative actions and demand letters. Following an investigation, the special committee determined that no action was warranted, and rejected the shareholders’ demands. The special committee’s determination has been communicated to counsel for the shareholders. Should the shareholders continue to pursue their claims in court, the Company will take appropriate steps to seek dismissal of the complaints. In February 2021, the Company received a subpoena from the Enforcement Division of the SEC requesting information from the Company relating to, among other things, Alaris TM infusion pumps. The Company is cooperating with the SEC and responding to these requests. The Company cannot anticipate the timing, scope, outcome or possible impact of the investigation, financial or otherwise. In April 2019, the Department of Justice served the Company and CareFusion with CIDs seeking information regarding certain of CareFusion’s contracts with the Department of Veteran’s Affairs for certain products, including Alaris TM and Pyxis TM devices, in connection with a civil investigation of possible violations of the False Claims Act, and the government recently expanded the investigation to include several additional contracts. The government has made several requests for documents and interviews or depositions of Company personnel. The Company is cooperating with the government and responding to these requests. In September 2021, the Company received a CID related to an inquiry initiated by the Northern District of Georgia in 2018. The requests concern sales and marketing practices with respect to certain aspects of the Company’s urology business. The government has made requests for documents and has interviewed employees. The inquiry is ongoing and the Company is cooperating with the government and responding to its requests. In September 2021, the Company was served with a complaint from the New Mexico Attorney General, alleging violations of the state’s consumer protection laws in connection with the sales and marketing of its IVC filters. The Company is preparing its initial response and intends to vigorously defend itself in the litigation. As the case is in its early stages, the Company cannot anticipate the timing, scope, outcome or possible impact at present. The Company cannot predict the outcome of these matters, nor can it predict whether any outcome will have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. Accordingly, the Company has made no provisions for these other legal matters in its consolidated results of operations. In July 2021, the Company became aware of lawsuits that had been filed against it in state and federal court in Georgia. The suits were filed by plaintiffs who reside near Company facilities in Covington, GA, where ethylene oxide (“EtO”) sterilization activities take place and currently number approximately 160. The claims allege a variety of injuries, including but not limited to multiple types of cancer, allegedly attributable to exposure to EtO in the ambient air. The Company has meritorious defenses and intends to defend itself vigorously. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters. Litigation Accruals The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time. During fiscal years 2021, 2020, and 2019, the Company recorded pre-tax charges to Other operating expense, net , of approximately $361 million, $378 million, and $914 million, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during fiscal years 2021 and 2020 including but not limited to: the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain product liability matters; the status of certain settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company and the stage of litigation. Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $2.5 billion at September 30, 2021 and 2020. These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other Liabilities on the Company's consolidated balance sheets. As of September 30, 2021 and 2020, the Company had $106 million and $92 million, respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash . The Company's expected recoveries related to product liability claims and related legal defense costs were approximately $93 million and $139 million at September 30, 2021 and 2020, respectively. The expected recoveries at September 30, 2021 related entirely to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. A substantial amount of the expected recoveries at September 30, 2020 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The expected recoveries at September 30, 2021 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements.

Revenues

Revenues	12 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenues As previously discussed in Note 2, the Company adopted ASC 606 in fiscal year 2019 using the modified retrospective method. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Timing of Revenue Recognition The Company's revenues are primarily recognized when the customer obtains control of the product sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized when customer acceptance of these installed products has been confirmed. For certain service arrangements, including extended warranty and software maintenance contracts, revenue is recognized ratably over the contract term. The majority of revenues relating to extended warranty contracts associated with certain instruments and equipment is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over a longer period. Measurement of Revenues The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. The Company considers its shipping and handling costs to be costs of contract fulfillment and has made the accounting policy election to record these costs within Selling and administrative expense . Payment terms extended to the Company's customers are based upon commercially reasonable terms for the markets in which the Company's products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company's agreements with its end-user customers. Additional factors considered in the estimate of the Company's rebate liability include the quantification of inventory that is either in stock at or in transit to the Company's distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The Company’s rebate liability at September 30, 2021 and 2020 was $576 million and $526 million, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Additional disclosures relating to sales discounts and sales returns are provided in Note 18. The Company's agreements with customers within certain organizational units including Medication Management Solutions, Integrated Diagnostic Solutions and Biosciences, contain multiple performance obligations including both products and certain services noted above. The transaction price for these agreements is allocated to each performance obligation based upon its relative standalone selling price. Standalone selling price is the amount at which the Company would sell a promised good or service separately to a customer. The Company generally estimates standalone selling prices using its list prices and a consideration of typical discounts offered to customers. Effects of Revenue Arrangements on Consolidated Balance Sheets Due to the nature of the majority of the Company's products and services, the Company typically does not incur costs to fulfill a contract in advance of providing the customer with goods or services. Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's consolidated balance sheets. The Company's costs to obtain contracts are comprised of sales commissions which are paid to the Company's employees or third party agents. The majority of the sales commissions incurred by the Company relate to revenue that is recognized over a period that is less than one year and as such, the Company has elected a practical expedient provided under ASC 606 to record the majority of its expense associated with sales commissions as it is incurred. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's consolidated balance sheets. The Company records contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time as discussed further above. These contract liabilities are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its consolidated balance sheets. Remaining Performance Obligations The Company's obligations relative to service contracts, which are further discussed above, and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided, are estimated to be approximately $2.1 billion at September 30, 2021. The Company expects to recognize the majority of this revenue over the next three years. Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.5 billion at September 30, 2021. This revenue will be recognized over the customer relationship periods. Disaggregation of Revenues A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.

Segment Data

Segment Data	12 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Data	Segment Data The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Medical Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Medication Delivery Solutions; Medication Management Solutions; Diabetes Care; Pharmaceutical Systems. Life Sciences Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians’ office practices; retail pharmacies; academic and government institutions; and pharmaceutical and biotechnology companies. With the emergency use authorization approval of the BD Veritor™ At-Home COVID-19 Test, Life Sciences also serves patients directly. Life Sciences consists of the following organizational units: Integrated Diagnostic Solutions and Biosciences. Interventional Interventional provides vascular, urology, oncology and surgical specialty products that are intended, with the exception of the V. Mueller TM surgical and laparoscopic instrumentation products, to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, individual healthcare professionals, extended care facilities, alternate site facilities and patients via the segment's Homecare business. Interventional consists of the following organizational units: Surgery; Peripheral Intervention; Urology and Critical Care. Additional Segment Information Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. The Company’s chief operating decision maker does not receive any asset information by business segment and, as such, the Company does not report asset information by business segment. Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. (Millions of dollars) 2021 2020 2019 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions $ 2,246 $ 1,812 $ 4,057 $ 1,972 $ 1,583 $ 3,555 $ 2,037 $ 1,811 $ 3,848 Medication Management Solutions 1,863 570 2,432 1,865 589 2,454 2,115 525 2,640 Diabetes Care 606 554 1,160 562 522 1,084 573 538 1,110 Pharmaceutical Systems 428 1,401 1,829 404 1,184 1,588 392 1,073 1,465 Total segment revenues $ 5,142 $ 4,336 $ 9,479 $ 4,802 $ 3,878 $ 8,680 $ 5,116 $ 3,947 $ 9,064 Life Sciences Integrated Diagnostic Solutions $ 2,477 $ 2,748 $ 5,225 $ 1,872 $ 1,659 $ 3,532 $ 1,446 $ 1,659 $ 3,106 Biosciences 503 802 1,305 465 678 1,143 485 709 1,194 Total segment revenues $ 2,980 $ 3,550 $ 6,530 $ 2,337 $ 2,337 $ 4,675 $ 1,931 $ 2,368 $ 4,300 Interventional Surgery $ 1,023 $ 274 $ 1,296 $ 891 $ 230 $ 1,121 $ 977 $ 264 $ 1,242 Peripheral Intervention 931 780 1,711 871 640 1,511 917 657 1,574 Urology and Critical Care 894 338 1,232 815 315 1,130 787 323 1,110 Total segment revenues $ 2,847 $ 1,392 $ 4,239 $ 2,577 $ 1,186 $ 3,762 $ 2,682 $ 1,244 $ 3,926 Total Company revenues $ 10,969 $ 9,279 $ 20,248 $ 9,716 $ 7,401 $ 17,117 $ 9,730 $ 7,560 $ 17,290 (Millions of dollars) 2021 2020 2019 Income Before Income Taxes Medical (a) (b) (c) $ 2,583 $ 2,274 $ 2,824 Life Sciences (d) 2,391 1,405 1,248 Interventional (e) 933 724 903 Total Segment Operating Income 5,907 4,403 4,976 Acquisitions and other restructurings (185) (309) (480) Unallocated other operating expense, net (f) (238) (363) (579) Net interest expense (460) (521) (627) Other unallocated items (g) (2,783) (2,224) (2,115) Total Income Before Income Taxes $ 2,242 $ 985 $ 1,176 Capital Expenditures Medical $ 777 $ 477 $ 577 Life Sciences 297 192 230 Interventional 125 119 120 Corporate and All Other 32 22 30 Total Capital Expenditures $ 1,231 $ 810 $ 957 Depreciation and Amortization Medical $ 1,140 $ 1,104 $ 1,073 Life Sciences 352 286 284 Interventional 769 750 881 Corporate and All Other 12 14 14 Total Depreciation and Amortization $ 2,273 $ 2,154 $ 2,253 (a) The amounts in 2021 and 2020 include charges of $56 million and $244 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for BD Alaris TM infusion pumps in the Medication Management Solutions unit . (b) The amount in 2020 included $41 million of charges to Cost of products sold to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units. (c) The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform. (d) The amount in 2020 included charges of $57 million recorded to Cost of products sold to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units. (e) The amount in 2019 included a charge of $30 million recorded to Research and development expense to write down the carrying value of certain intangible assets in the Surgery unit. (f) The amounts in 2021, 2020 and 2019 include pre-tax charges of $361 million, $378 million and $914 million, respectively, related to certain product liability matters, which is further discussed in Note 5. The amount in 2021 also includes gains of $158 million on sale-leaseback transactions, which are further discussed in Note 17, and $35 million of costs incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business. The 2019 amount also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million, which is further discussed in Note 10. (g) Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. Geographic Information The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which is comprised of Latin America (which includes Mexico, Central America, the Caribbean and South America) and Canada. Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. (Millions of dollars) 2021 2020 2019 Revenues United States $ 10,969 $ 9,716 $ 9,730 EMEA (a) 4,751 3,928 3,837 Greater Asia 3,272 2,568 2,726 Other (a) 1,255 905 997 $ 20,248 $ 17,117 $ 17,290 Long-Lived Assets United States $ 36,037 $ 36,468 $ 37,053 EMEA (a) 6,004 5,890 5,519 Greater Asia 1,662 1,521 1,328 Other (a) 860 753 824 Corporate 465 411 377 $ 45,029 $ 45,043 $ 45,101 (a) The amounts in fiscal years 2020 and 2019 reflect the reclassifications of $448 million and $478 million, respectively, of revenues and $55 million and $37 million, respectively, of long-lived assets in the Middle East and Africa.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based CompensationThe Company grants share-based awards under the 2004 Employee and Director Equity-Based Compensation Plan (“2004 Plan”), which provides long-term incentive compensation to employees and directors consisting of: stock appreciation rights (“SARs”), performance-based restricted stock units, time-vested restricted stock units and other stock awards. The fair value of share-based payments is recognized as compensation expense in net income. BD estimates forfeitures based on experience at the time of grant and adjusts expense to reflect actual forfeiture s. The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2021 2020 2019 Cost of products sold $ 43 $ 40 $ 37 Selling and administrative expense 158 150 145 Research and development expense 36 34 32 Acquisitions and other restructurings 1 20 50 $ 238 $ 245 $ 265 Tax benefit associated with share-based compensation costs recognized $ 55 $ 57 $ 62 Upon the Company's acquisition of Bard in 2018, certain pre-acquisition equity awards of Bard were converted into either BD SARs or BD restricted stock awards, as applicable. These awards have substantially the same terms and conditions as the converted Bard awards immediately prior to the acquisition date. Compensation expense of $16 million and $40 million associated with these replacement awards was recorded in Acquisitions and other restructurings in 2020 and 2019, respectively. Stock Appreciation Rights SARs represent the right to receive, upon exercise, shares of common stock having a value equal to the difference between the market price of common stock on the date of exercise and the exercise price on the date of grant. SARs generally vest over a period of four years and have a term of ten years. The fair value of awards was estimated on the date of grant using a lattice-based binomial option valuation model and these valuations were largely based upon the following weighted-average assumptions: 2021 2020 2019 Risk-free interest rate 0.68% 1.69% 3.05% Expected volatility 23.0% 19.0% 18.0% Expected dividend yield 1.46% 1.24% 1.27% Expected life 7.4 years 7.4 years 7.2 years Fair value derived $44.38 $48.82 $51.86 Expected volatility is based upon historical volatility for the Company’s common stock and other factors. The expected life of SARs granted is derived from the output of the lattice-based model, using assumed exercise rates based on historical exercise and termination patterns, and represents the period of time that SARs granted are expected to be outstanding. The risk-free interest rate used is based upon the published U.S. Treasury yield curve in effect at the time of grant for instruments with a similar life. The dividend yield is based upon the most recently declared quarterly dividend as of the grant date. The Company issued 0.4 million shares during 2021 to satisfy the SARs exercised. A summary of SARs outstanding as of September 30, 2021 and changes during the year then ended is as follows: SARs (in Weighted Weighted Aggregate Balance at October 1 6,337 $ 167.17 Granted 1,097 227.83 Exercised (842) 128.13 Forfeited, canceled or expired (297) 237.47 Balance at September 30 6,295 $ 179.64 5.51 $ 424 Vested and expected to vest at September 30 6,113 $ 177.94 5.42 $ 421 Exercisable at September 30 4,471 $ 156.28 4.31 $ 403 A summary of SARs exercised during 2021, 2020 and 2019 is as follows: (Millions of dollars) 2021 2020 2019 Total intrinsic value of SARs exercised $ 102 $ 212 $ 260 Total fair value of SARs vested $ 39 $ 46 $ 66 Performance-Based and Time-Vested Restricted Stock Units Performance-based restricted stock units cliff vest three years after the date of grant. These units are tied to the Company’s performance against pre-established targets over a performance period of three years. The performance measures for fiscal years 2021 and 2020 were average annual currency-neutral revenue growth and average annual return on invested capital, with the combined factor subject to adjustment based on the Company's relative total shareholder return (measures the Company’s stock performance during the performance period against that of peer companies). For fiscal year 2019, the performance measures were relative total shareholder return and average annual return on invested capital. Under the Company’s long-term incentive program, the actual payout under these awards may vary from zero to 200% of an employee’s target payout, based on the Company’s actual performance over the performance period of three years. In fiscal years 2021 and 2020, the Company also issued additional performance-based time-vested units to certain key executives, which cliff vest three years after the date of grant and are tied to the Company’s performance against average annual growth in the Company’s Adjusted EPS over a performance period of three years. No shares will be issuable if the performance targets have not been met. The fair value is based on the market price of the Company’s stock on the date of grant. Compensation cost initially recognized assumes that the target payout level will be achieved and is adjusted for subsequent changes in the expected outcome of performance-related conditions. For units for which the performance conditions are modified after the date of grant, any incremental increase in the fair value of the modified units, over the original units, is recorded as compensation expense on the date of the modification for vested units, or over the remaining performance period for units not yet vested. Time-vested restricted stock unit awards vest on a graded basis over a period of three years, except for certain key executives of the Company, including the executive officers, for which such units generally vest one year following the employee’s retirement. The related share-based compensation expense is recorded over the requisite service period, which is the vesting period or is based on retirement eligibility. The fair value of all time-vested restricted stock units is based on the market value of the Company’s stock on the date of grant. A summary of restricted stock units outstanding as of September 30, 2021 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in Weighted Stock Units (in Weighted Balance at October 1 962 $ 244.42 1,697 $ 226.01 Granted 406 216.39 881 223.60 Distributed (39) 252.57 (601) 231.44 Forfeited or canceled (373) 245.86 (421) 231.29 Balance at September 30 957 (a) $ 231.63 1,556 $ 221.11 Expected to vest at September 30 339 (b) $ 227.92 1,478 $ 220.60 (a) Based on 200% of target payout for performance based restricted units and 100% of the performance based time-vested units. (b) Net of expected forfeited units and units in excess of the expected performance payout of 63 thousand and 555 thousand shares, respectively. The weighted average grant date fair value of restricted stock units granted during the years 2021, 2020 and 2019 are as follows: Performance-Based Time-Vested 2021 2020 2019 2021 2020 2019 Weighted average grant date fair value of units granted $ 216.39 $ 245.06 $ 237.55 $ 223.60 $ 249.94 $ 235.50 The total fair value of stock units vested during 2021, 2020 and 2019 was as follows: Performance-Based Time-Vested (Millions of dollars) 2021 2020 2019 2021 2020 2019 Total fair value of units vested $ 16 $ 27 $ 33 $ 203 $ 211 $ 254 At September 30, 2021, the weighted average remaining vesting term of performance-based and time vested restricted stock units is 1.27 and 0.89 years, respectively. Unrecognized Compensation Expense and Other Stock Plans The amount of unrecognized compensation expense for all non-vested share-based awards as of September 30, 2021, is approximately $247 million, which is expected to be recognized over a weighted-average remaining life of approximately 1.94 years. At September 30, 2021, 8.6 million shares were authorized for future grants under the 2004 Plan. The Company has a policy of satisfying share-based payments through either open market purchases or shares held in treasury. At September 30, 2021, the Company has sufficient shares held in treasury to satisfy these payments. As of September 30, 2021, 93 thousand shares were held in trust relative to a Director's Deferral plan, which provides a means to defer director compensation, from time to time, on a deferred stock or cash basis. Also as of September 30, 2021, 259 thousand shares were issuable under a Deferred Compensation Plan that allows certain highly-compensated employees, including executive officers, to defer salary, annual incentive awards and certain equity-based compensation.

Benefit Plans

Benefit Plans	12 Months Ended
	Sep. 30, 2021
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. Postretirement healthcare and life insurance benefits provided to qualifying domestic retirees as well as other postretirement benefit plans in international countries are not material. The measurement date used for the Company’s employee benefit plans is September 30. As a result of the Company’s conclusion to merge the legacy Bard pension plan into the BD defined benefit cash balance pension plan, the assets and liabilities of the legacy Bard U.S. defined pension benefit plan were remeasured as of October 31, 2020. Amendments to this plan were approved and communicated to affected employees in the first quarter of fiscal year 2021. The legacy Bard U.S. pension plan has been frozen to prevent new participants since January 1, 2011. Effective January 1, 2018, the legacy BD U.S. pension plan was frozen to limit the participation of employees who are hired or re-hired by the Company, or who transfer employment to the Company, on or after January 1, 2018. Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2021 2020 2019 Service cost $ 150 $ 153 $ 134 Interest cost 71 84 107 Expected return on plan assets (174) (188) (180) Amortization of prior service credit (16) (13) (13) Amortization of loss 97 97 78 Curtailment/settlement loss 9 4 10 Net pension cost $ 137 $ 137 $ 135 Net pension cost included in the preceding table that is attributable to international plans $ 41 $ 41 $ 32 The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. The settlement losses recorded in 2021, 2020 and 2019 included lump sum benefit payments associated with certain plans. The Company recognizes pension settlements when payments from the plan exceed the sum of service and interest cost components of net periodic pension cost associated with the plan for the fiscal year. A curtailment loss in 2021, related to freezing a pension plan in Europe, was recorded when the loss was probable and estimable. All components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other (expense) income, net on its consolidated statements of income. The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2021 2020 Change in benefit obligation: Beginning obligation $ 3,953 $ 3,731 Service cost 150 153 Interest cost 71 84 Plan amendments (30) — Benefits paid (156) (186) Impact of acquisitions — 10 Actuarial (gain) loss (69) 104 Curtailments/settlements (49) (17) Other, includes translation 19 74 Benefit obligation at September 30 $ 3,889 $ 3,953 Change in fair value of plan assets: Beginning fair value $ 3,045 $ 2,926 Actual return on plan assets 317 222 Employer contribution 66 42 Benefits paid (156) (186) Impact of acquisitions — 7 Settlements (55) (17) Other, includes translation 5 51 Plan assets at September 30 $ 3,222 $ 3,045 Funded Status at September 30: Unfunded benefit obligation $ (667) $ (908) Amounts recognized in the Consolidated Balance Other $ 29 $ 16 Salaries, wages and related items (29) (23) Long-term Employee Benefit Obligations (667) (901) Net amount recognized $ (667) $ (908) Amounts recognized in Accumulated other Prior service credit $ 41 $ 31 Net actuarial loss (972) (1,281) Net amount recognized $ (931) $ (1,250) International pension plan assets at fair value included in the preceding table were $1.033 billion and $935 million at September 30, 2021 and 2020, respectively. The international pension plan projected benefit obligations were $1.320 billion and $1.321 billion at September 30, 2021 and 2020, respectively. The benefit obligation associated with postretirement healthcare and life insurance plans provided to qualifying domestic retirees, which was largely recorded to Long-Term Employee Benefit Obligations, was $138 million and $148 million at September 30, 2021 and 2020, respectively. Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Projected Benefit (Millions of dollars) 2021 2020 2021 2020 Projected benefit obligation $ 3,475 $ 3,920 Accumulated benefit obligation $ 3,309 $ 3,703 Fair value of plan assets $ 2,712 $ 2,936 $ 2,780 $ 2,996 The weighted average assumptions used in determining pension plan information were as follows: 2021 2020 2019 Net Cost Discount rate: U.S. plans (a) 2.80 % 3.21 % 4.26 % International plans 1.44 1.39 2.30 Expected return on plan assets: U.S. plans 6.25 7.25 7.25 International plans 4.92 5.05 4.98 Rate of compensation increase: U.S. plans 4.30 4.29 4.29 International plans 2.20 2.35 2.36 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 1.95 1.97 1.84 Benefit Obligation Discount rate: U.S. plans 2.89 2.80 3.21 International plans 1.75 1.44 1.39 Rate of compensation increase: U.S. plans 4.31 4.30 4.29 International plans 2.63 2.20 2.35 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 2.02 1.95 1.97 (a) The Company calculated the service and interest components utilizing an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. Expected Rate of Return on Plan Assets The expected rate of return on plan assets is based upon expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, the Company considers many factors, including historical assumptions compared with actual results; benchmark data; expected returns on various plan asset classes, as well as current and expected asset allocations. Expected Funding The Company’s funding policy for its defined benefit pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that may be appropriate considering the funded status of the plans, tax consequences, the cash flow generated by the Company and other factors. The Company made discretionary contributions to its BD U.S. pension plan of $16 million during fiscal year 2021 and $134 million in October 2021. The Company did not make any required contributions in 2021 and does not anticipate any significant required contributions to its pension plans in 2022. Expected benefit payments are as follows: (Millions of dollars) Pension 2022 $ 242 2023 174 2024 178 2025 189 2026 206 2027-2031 1,113 Expected benefit payments associated with postretirement healthcare plans are immaterial to the Company's consolidated financial results. Investments The Company’s primary objective is to achieve returns sufficient to meet future benefit obligations. It seeks to generate above market returns by investing in more volatile asset classes such as equities while at the same time controlling risk through diversification in non-correlated asset classes and through allocations to more stable asset classes like fixed income. U.S. Plans The Company’s U.S. pension plans comprise 68% of total benefit plan investments, based on September 30, 2021 market values, and have a target asset mix of 45% fixed income, 23% diversifying investments and 32% equities. This mix was established based on an analysis of projected benefit payments and estimates of long-term returns, volatilities and correlations for various asset classes. The asset allocations to diversifying investments include high-yield bonds, hedge funds, real estate, infrastructure, leveraged loans and emerging markets bonds. The actual portfolio investment mix may, from time to time, deviate from the established target mix due to various factors such as normal market fluctuations, the reliance on estimates in connection with the determination of allocations and normal portfolio activity such as additions and withdrawals. Rebalancing of the asset portfolio on a quarterly basis is required to address any allocations that deviate from the established target allocations in excess of defined allowable ranges. The target allocations are subject to periodic review, including a review of the asset portfolio’s performance, by the named fiduciary of the plans. Any tactical deviations from the established asset mix require the approval of the named fiduciary. The U.S. plans may enter into both exchange traded and non-exchange traded derivative transactions in order to manage interest rate exposure, volatility, term structure of interest rates, and sector and currency exposures within the fixed income portfolios. The Company has established minimum credit quality standards for counterparties in such transactions. The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2021 and 2020. The categorization of fund investments is based upon the categorization of these funds’ underlying assets. Basis of fair value measurement (See Note 1) (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Level 1 Level 2 Level 3 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Fixed Income: Corporate bonds $ 679 $ 656 $ — $ — $ 297 $ 273 $ 382 $ 383 $ — $ — Government and agency-U.S. 184 95 — — 162 74 22 21 — — Government and agency-Foreign 46 40 — — — — 46 40 — — Other fixed income 141 141 — — — — 141 141 — — Equity securities 686 737 43 43 643 694 — — — — Cash and cash equivalents 168 147 — — 168 147 — — — — Other 286 291 152 151 135 141 — — — — Fair value of plan assets $ 2,189 $ 2,108 $ 195 $ 193 $ 1,405 $ 1,330 $ 590 $ 584 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator. Fixed Income Securities U.S. pension plan assets categorized above as fixed income securities include fund investments comprised of corporate and government and agency investments. Investments in corporate bonds are diversified across industry and sector and consist of investment-grade, as well as high-yield debt instruments. U.S. government investments consist of obligations of the U.S. Treasury, other U.S. government agencies, state governments and local municipalities. Assets categorized as foreign government and agency debt securities included investments in developed and emerging markets. The values of fixed income investments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. A portion of the fixed income instruments classified within Level 2 are valued based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. Equity Securities U.S. pension plan assets categorized as equity securities consist of fund investments in publicly-traded U.S. and non-U.S. equity securities. In order to achieve appropriate diversification, these portfolios are invested across market sectors, investment styles, capitalization weights and geographic regions. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded or have a readily determinable fair value based on published prices obtained from fund managers which represent the price at which the instruments can be redeemed at period end. The U.S. pension plan has no future funding commitments associated with these investments and has the right to redeem them upon one day’s notice, at any time and without restriction. Cash and Cash Equivalents A portion of the U.S. plans’ assets consists of investments in cash and cash equivalents, primarily to accommodate liquidity requirements relating to trade settlement and benefit payment activity, and the values of these assets are based upon quoted market prices. Other Securities Other U.S. pension plan assets include fund investments comprised of hedge funds. The values of such instruments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. International Plans International plan assets comprise 32% of the Company’s total benefit plan assets, based on market value at September 30, 2021. Such plans have local independent fiduciary committees, with responsibility for development and oversight of investment policy, including asset allocation decisions. In making such decisions, consideration is given to local regulations, investment practices and funding rules. The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2021 and 2020. Basis of fair value measurement (See Note 1) (Millions of dollars) Total International Investments Measured at Net Asset Value Level 1 Level 2 Level 3 (a) 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Fixed Income: Corporate bonds $ 55 $ 34 $ — $ — $ 37 $ 15 $ 18 $ 19 $ — $ — Government and agency-U.S. 13 3 — — 10 — 3 3 — — Government and agency-Foreign 264 212 — — 249 115 15 97 — — Other fixed income 121 102 — — 72 63 49 39 — — Equity securities 297 335 — — 297 335 — — — — Cash and cash equivalents 14 12 — — 14 12 — — — — Real estate 44 34 — — 2 — 31 24 11 10 Insurance contracts 118 131 — — — — — — 118 131 Other 107 72 — — 84 70 8 1 15 — Fair value of plan assets $ 1,033 $ 935 $ — $ — $ 765 $ 611 $ 124 $ 183 $ 145 $ 141 (a) Changes in the fair value of international pension assets measured using Level 3 inputs for the years ended September 30, 2021 and 2020 were immaterial. Fixed Income Securities Fixed income investments held by international pension plans include corporate, U.S. government and non-U.S. government securities. The values of fixed income securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Values of investments classified within Level 2 are based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources. Equity Securities Equity securities included in the international plan assets consist of publicly-traded U.S. and non-U.S. equity securities. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded or have a readily determinable fair value based on published prices obtained from fund managers which represent the price at which the instruments can be redeemed at period end. The international plans holding these securities have no future funding commitments associated with these investments and has the right to redeem them upon one day’s notice, at any time and without restriction. Other Securities The international plans hold a portion of assets in cash and cash equivalents, in order to accommodate liquidity requirements and the values are based upon quoted market prices. Real estate investments consist of investments in funds holding an interest in real properties and the corresponding values represent the estimated fair value based on the fair value of the underlying investment value or cost, adjusted for any accumulated earnings or losses. The values of insurance contracts approximately represent cash surrender value. Other investments include fund investments for which values are based upon either quoted market prices or market observable sources. Defined Contribution Plans The cost of voluntary defined contribution plans which provide for a Company match or contribution was $153 million in 2021, $111 million in 2020 and $126 million in 2019. As a short term measure to preserve cash and reduce costs, the Company's matching contributions were temporarily suspended effective May 1, 2020 and matching contributions were reinstated in October 2020.

Divestiture

Divestiture	12 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	Divestitures In October 2018, the Company completed the sale of its Life Sciences segment's Advanced Bioprocessing business. The Company recognized a pre-tax gain on the sale of approximately $336 million which was recorded as a component of Other operating expense, net

Business Restructuring Charges

Business Restructuring Charges	12 Months Ended
	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Business Restructuring Charges	Business Restructuring Charges In connection with the Company's 2018 acquisition of Bard, and simplification and other cost saving initiatives, the Company incurred restructuring costs which were largely recorded within Acquisitions and other restructurings on its consolidated statements of income. The simplification and other costs saving initiatives are focused on reducing complexity, enhancing product quality, refining customer experience, and improving cost efficiency across all of the Company’s segments. Restructuring liability activity in 2021, 2020 and 2019 was as follows: Employee Termination Other Total (Millions of dollars) Bard Other Initiatives (a) Bard (b) Other Initiatives (a) Bard Other Initiatives (a) Balance at September 30, 2018 $ 33 $ 23 $ — $ 4 $ 33 $ 27 Charged to expense 23 29 95 33 118 62 Cash payments (34) (21) (5) (31) (39) (52) Non-cash settlements — — (89) (3) (89) (3) Balance at September 30, 2019 $ 22 $ 31 $ 1 $ 3 $ 23 $ 34 Charged to expense 7 13 42 33 49 46 Cash payments (14) (27) (18) (31) (32) (58) Non-cash settlements — — (24) (2) (24) (2) Balance at September 30, 2020 $ 15 $ 17 $ 1 $ 3 $ 16 $ 20 Charged to expense 1 13 2 34 3 47 Cash payments (5) (26) (2) (29) (7) (55) Non-cash settlements — — — (4) — (4) Other adjustments (1) — — — (1) — Balance at September 30, 2021 $ 10 $ 4 $ 1 $ 4 $ 11 $ 8 (a) Restructuring costs in 2021, 2020 and 2019 included expenses primarily related to simplification and other cost saving initiatives. (b) Expenses in 2020 and 2019 largely represented the costs associated with the conversion of certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date.

Intangible Assets

Intangible Assets	12 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets at September 30 consisted of: 2021 2020 (Millions of dollars) Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Amortized intangible assets Developed technology $ 14,399 $ (4,983) $ 9,417 $ 14,105 $ (3,959) $ 10,146 Customer relationships 4,658 (1,839) 2,818 4,616 (1,509) 3,107 Product rights 123 (83) 40 119 (73) 46 Trademarks 409 (137) 271 408 (120) 288 Patents and other 533 (342) 191 500 (320) 180 Amortized intangible assets $ 20,122 $ (7,385) $ 12,737 $ 19,748 $ (5,981) $ 13,767 Unamortized intangible assets Acquired in-process research and development $ 44 $ 44 Trademarks 2 2 Unamortized intangible assets $ 46 $ 46 Intangible amortization expense was $1.403 billion, $1.384 billion and $1.497 billion in 2021, 2020 and 2019, respectively. The estimated aggregate amortization expense for the fiscal years ending September 30, 2022 to 2026 are as follows: 2022 — $1.399 billion; 2023 — $1.386 billion; 2024 — $1.384 billion; 2025 — $1.383 billion; 2026 — $1.357 billion. The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2019 $ 9,989 $ 772 $ 12,615 $ 23,376 Acquisitions (a) 10 58 49 117 Purchase price allocation adjustments — 1 4 5 Currency translation 44 7 71 122 Goodwill as of September 30, 2020 $ 10,044 $ 837 $ 12,739 $ 23,620 Acquisitions (a) 193 — 72 264 Purchase price allocation adjustments 4 — 1 6 Currency translation 15 (1) (2) 12 Goodwill as of September 30, 2021 $ 10,255 $ 836 $ 12,810 $ 23,901

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging ActivitiesThe Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items had on the Company’s balance sheets and the fair values of the derivatives outstanding at September 30, 2021 and 2020 were not material. The effects on the Company’s financial performance and cash flows are provided below. Foreign Currency Risks and Related Strategies The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with certain instruments such as foreign currency-denominated debt and cross-currency swaps, which are designated as net investment hedges, as well as currency exchange contracts. The notional amounts of the Company’s foreign currency-related derivative instruments as of September 30, 2021 and 2020 were as follows: (Millions of dollars) Hedge Designation 2021 2020 Foreign exchange contracts (a) Undesignated $ 2,735 $ 2,519 Foreign currency-denominated debt (b) Net investment hedges 2,543 1,522 Cross-currency swaps (c) Net investment hedges 1,958 2,971 (a) Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other (expense) income, net , during the years ending September 30, 2021, 2020 and 2019 are detailed in Note 18. (b) Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. (c) Represents cross-currency swaps which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss) . Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated. Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges as of September 30, 2021, 2020 and 2019 were as follows: (Millions of dollars) 2021 2020 2019 Foreign currency-denominated debt $ 32 $ (106) $ 138 Cross-currency swaps (a) (21) (109) 73 Foreign currency forward contract (b) — — (9) (a) The amount in 2021 includes a loss of $35 million recognized on terminated cross-currency swaps. (b) The amount in 2019 represented a loss recognized on a forward contract which was entered into and terminated in fiscal year 2019. Interest Rate Risks and Related Strategies The Company uses a mix of fixed and variable rate debt, which is further discussed in Note 15, to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges. Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss) . If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in Interest expense within the next 12 months is $1 million, net of tax. The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during 2021, 2020 and 2019 were not material to the Company's consolidated financial results. The Company recorded net after-tax gains (losses) of $72 million and $(75) million in Other comprehensive income (loss) relating to interest rate-related cash flow hedges during the years ended September 30, 2021 and 2020, respectively. The amounts recognized in other comprehensive income relating to interest rate hedges during the year ended 2019 were immaterial. For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. The amounts recorded during the years ended September 30, 2021 and 2020 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results. The notional amounts of the Company’s interest rate-related derivative instruments as of September 30, 2021 and 2020 were as follows: (Millions of dollars) Hedge Designation 2021 2020 Interest rate swaps (a) Fair value hedges $ 700 $ 375 Forward starting interest rate swaps (b) Cash flow hedges 1,000 1,500 (a) Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. In fiscal year 2021, certain interest rate swaps were terminated at an immaterial net gain, concurrently with the redemption of the 3.125% notes due November 8, 2021. (b) Represents interest rate derivatives entered into to mitigate exposure to interest rate risk related to future debt issuances. Concurrently with the issuance of senior unsecured U.S. notes in the second quarter of fiscal year 2021, the notional amount of $500 million of the Company's outstanding forward starting interest rate swaps were terminated at an immaterial net loss. Other Risk Exposures The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company had no outstanding commodity derivative forward contracts at September 30, 2021 and 2020.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value MeasurementsThe following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at September 30, 2021 and 2020 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) 2021 2020 Cash and equivalents $ 2,283 $ 2,825 Restricted cash 109 92 Cash and equivalents and restricted cash $ 2,392 $ 2,917 The fair values of the Company’s financial instruments are as follows: (Millions of dollars) Basis of fair value measurement (See Note 1) 2021 2020 Institutional money market accounts and ultra-short bond fund (a) Level 1 $ 200 $ 1,549 Current portion of long-term debt (b) Level 2 503 702 Long-term debt (b) Level 2 18,537 18,970 (a) These financial instruments are recorded within Cash and equivalents on the consolidated balance sheets. The institutional money market accounts permit daily redemption. Remaining cash and equivalents, excluding restricted cash, were $2.083 billion and $1.276 billion at September 30, 2021 and 2020, respectively. (b) Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year. All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets. Nonrecurring Fair Value Measurements In fiscal year 2021, the Company recorded charges to Cost of products sold of $49 million to write down the carrying value of certain fixed assets. In fiscal year 2020, the Company recorded charges to Cost of products sold of $57 million to write down the carrying values of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units, and $41 million to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units. In fiscal year 2019, the Company recorded a charge to Research and development expense of $30 million to write down the carrying values of certain intangible assets in the Surgery unit. The amounts recognized in 2021, 2020 and 2019 were recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using Level 3 inputs, including values estimated using the income approach. Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on its financial position or liquidity. Transfers of trade receivables Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The amounts transferred and yet to be remitted under factoring arrangements in 2021 and 2020 are provided below. The Company’s transfers of trade receivables during fiscal year 2019 were not material to its consolidated financial results. (Millions of dollars) 2021 2020 Trade receivables transferred to third parties under factoring arrangements $ 1,302 $ 2,163 Amounts yet to be collected and remitted to the third parties 130 256

Debt

Debt	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt Short-term debt The carrying value of Short-term debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2021 2020 Current portion of long-term debt 0.174% Notes due June 4, 2021 (a) $ — $ 701 Floating Rate Notes due June 6, 2022 500 — Other — 5 Total short-term debt $ 500 $ 707 (a) All of the aggregate principal amount outstanding was retired during 2021, as further discussed below. The weighted average interest rates for short-term debt were 1.15% and 0.20% at September 30, 2021 and 2020, respectively. Long-term debt The carrying value of Long-Term Debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2021 2020 3.125% Notes due November 8, 2021 (a) $ — $ 1,008 2.894% Notes due June 6, 2022 (a) — 1,797 Floating Rate Notes due June 6, 2022 — 499 1.000% Notes due December 15, 2022 579 584 3.300% Notes due March 1, 2023 (a) — 295 1.401% Notes due May 24, 2023 347 350 0.632% Notes due June 4, 2023 926 933 0.000% Notes due August 13, 2023 (b) 463 — 3.875% Notes due May 15, 2024 (a) 146 180 3.363% Notes due June 6, 2024 (a) 994 1,742 3.734% Notes due December 15, 2024 (a) 873 1,370 3.020% Notes due May 24, 2025 336 320 0.034% Notes due August 13, 2025 (b) 577 — 1.208% Notes due June 4, 2026 693 699 6.700% Notes due December 1, 2026 168 172 1.900% Notes due December 15, 2026 577 582 3.700% Notes due June 6, 2027 1,716 1,715 7.000% Debentures due August 1, 2027 174 175 6.700% Debentures due August 1, 2028 173 174 0.334% Notes due August 13, 2028 (b) 1,037 — 2.823% Notes due May 20, 2030 744 743 1.957% Notes due February 11, 2031 (b) 992 — 1.213% Notes due February 12, 2036 (b) 690 — 6.000% Notes due May 15, 2039 246 246 5.000% Notes due November 12, 2040 124 124 1.336% Notes due August 13, 2041 (b) 1,034 — 4.875% Notes due May 15, 2044 246 247 4.685% Notes due December 15, 2044 1,033 1,044 4.669% Notes due June 6, 2047 1,481 1,485 3.794% Notes due May 20, 2050 742 742 Total Long-Term Debt $ 17,110 $ 17,224 (a) All or a portion of the aggregate principal amount outstanding was retired during 2021, as further discussed below. (b) Represents notes issued during 2021, as further discussed below. The aggregate annual maturities of Long-Term Debt including interest during the fiscal years ending September 30, 2022 to 2026 are as follows: 2022 — $433 million; 2023 — $2.749 billion; 2024 — $1.559 billion; 2025 — $2.164 billion; 2026 — $1.053 billion. Other current credit facilities During the fourth quarter of fiscal year 2021, the Company refinanced its five-year senior unsecured revolving credit facility that was to expire in December 2022, with a new five-year senior unsecured revolving credit facility that will expire in September 2026. The credit facility provides borrowings of up to $2.75 billion, with separate sub-limits of $100 million for letters of credit and swingline loans. The expiration date of the credit facility may be extended for up to two additional one year periods, subject to certain restrictions (including the consent of the lenders). The credit facility provides that the Company may, subject to additional commitments by lenders, request an additional $500 million of financing, for a maximum aggregate commitment under the credit facility of up to $3.25 billion. Proceeds from this facility may be used for general corporate purposes. There were no borrowings outstanding under the Company’s revolving credit facilities as of September 30, 2021 and 2020. In addition, the Company has informal lines of credit outside of the United States. The Company had no commercial paper borrowings outstanding as of September 30, 2021. Debt issuances The Company issued the following U.S. dollar-denominated debt during fiscal years 2021 and 2020: Interest rate and maturity Period issued Amount issued (millions of dollars) Use of proceeds 1.957% notes due February 11, 2031 Second quarter 2021 $ 1,000 Retirement of 3.125% notes due November 8, 2021 2.823% notes due May 20, 2030 Third quarter 2020 750 Retirements of 2.404% notes due June 5, 2020 and 3.250% notes due November 12, 2020 3.794% notes due May 20, 2050 Third quarter 2020 750 Retirements of 2.404% notes due June 5, 2020 and 3.250% notes due November 12, 2020 The Company issued the following Euro-denominated debt during fiscal year 2021: Interest rate and maturity Period issued Amount issued (millions of Euros) Amount issued (millions of dollars) Use of proceeds 0.000% notes due August 13, 2023 Fourth quarter 2021 € 400 $ 470 Fourth quarter 2021 retirements detailed below 0.034% notes due August 13, 2025 Fourth quarter 2021 500 587 Fourth quarter 2021 retirements detailed below Also in fiscal year 2021, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée), which is an indirect, wholly-owned finance subsidiary of the Company, issued Euro-denominated notes, listed below, which are fully and unconditionally guaranteed on a senior unsecured basis by the Company. No other of the Company's subsidiaries provide any guarantees with respect to these notes. The indenture covenants included a limitation on liens and a restriction on sale and leasebacks, change of control and consolidation, merger and sale of assets covenants. These covenants are subject to a number of exceptions, limitations and qualifications. The indenture does not restrict the Company, Becton Dickinson Euro Finance S.à r.l., or any other of the Company's subsidiaries from incurring additional debt or other liabilities, including additional senior debt. Additionally, the indenture does not restrict Becton Dickinson Euro Finance S.à r.l. and the Company from granting security interests over its assets. The notes issued by Becton Dickinson Euro Finance S.à r.l included the following: Interest rate and maturity Period issued Amount issued (millions of Euros) Amount issued (millions of dollars) Use of proceeds 0.334% notes due August 13, 2028 Fourth quarter 2021 € 900 $ 1,055 Fourth quarter 2021 retirements detailed below 1.336% notes due August 13, 2041 Fourth quarter 2021 900 1,055 Fourth quarter 2021 retirements detailed below 1.213% notes due February 12, 2036 Second quarter 2021 600 728 Retirement of 0.174% notes due June 4, 2021 Debt retirements The Company’s retirements of debt in fiscal year 2021 included the following: (millions of dollars) Principal, interest rate and maturity Period of retirement Carrying value Market price of retirement (a) Loss recognized to Other (expense) income, net (b) $1.535 billion of 2.894% notes due June 6, 2022 Fourth quarter 2021 $ 1,534 $ 1,566 $ 32 $294 million of 3.300% notes due March 1, 2023 Fourth quarter 2021 295 307 12 $33 million of 3.875% notes due May 15, 2024 Fourth quarter 2021 33 35 2 $500 million of 3.734% notes due December 15, 2024 Fourth quarter 2021 499 546 48 $752 million of 3.363% notes due June 6, 2024 Fourth quarter 2021 750 808 58 $1.0 billion of 3.125% notes due November 8, 2021 Second quarter 2021 1,005 1,019 14 600 million Euros ($728 million) of 0.174% notes due June 4, 2021 Second quarter 2021 728 730 1 $265 million of 2.894% notes due June 6, 2022 First quarter 2021 265 275 10 (a) Included accrued interest, related premiums, fees and expenses. (b) All debt retirements in fiscal year 2021 were accounted for as early debt extinguishments. The Company’s retirements of debt in fiscal year 2020 included the following: (millions of dollars) Principal, interest rate and maturity Period of retirement Carrying value Market price of retirement (a) Loss recognized to Other (expense) income, net $200 million of 3.250% notes due November 12, 2020 and $750 million of floating rate notes due December 29, 2020 (b) Fourth quarter 2020 $ 950 $ 951 $ 1 $1.0 billion of 2.404% notes due June 5, 2020 Third quarter 2020 1,000 1,000 — $500 million of 3.250% notes due November 12, 2020 (b) Third quarter 2020 500 506 6 (a) Included accrued interest, related premiums, fees and expenses. (b) Debt retirement was accounted for as an early debt extinguishment. In March 2020, the Company entered into a 364-day senior unsecured term loan facility with borrowing capacity available of $2.0 billion. During the third quarter of fiscal year 2020, the Company repaid $1.9 billion of borrowings outstanding under this term loan with cash on hand and terminated the facility. Capitalized interest The Company capitalizes interest costs as a component of the cost of construction in progress. A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2021 2020 2019 Charged to operations $ 469 $ 528 $ 639 Capitalized 44 43 44 Total interest costs $ 512 $ 571 $ 683 Interest paid, net of amounts capitalized $ 474 $ 515 $ 658

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Provision for Income Taxes The provision (benefit) for income taxes the years ended September 30 consisted of: (Millions of dollars) 2021 2020 2019 Current: Federal $ 102 $ (50) $ 235 State and local, including Puerto Rico 46 47 41 Foreign 290 400 300 $ 438 $ 397 $ 576 Deferred: Domestic $ (286) $ (184) $ (577) Foreign (2) (101) (56) (288) (286) (633) Income tax provision (benefit) $ 150 $ 111 $ (57) The components of Income Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2021 2020 2019 Domestic, including Puerto Rico $ 133 $ (489) $ 799 Foreign 2,109 1,474 377 Income Before Income Taxes $ 2,242 $ 985 $ 1,176 U.S. tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the "Act"), was enacted on December 22, 2017. The Act reduced the U.S. federal corporate tax rate from 35% to 21%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and created new taxes on certain foreign-sourced earnings. The Act subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The Company has elected to account for its GILTI tax due as a period expense in the year the tax is incurred. During fiscal year 2019, the Company finalized its accounting for the income tax effects of the Act and recognized additional tax benefit of $50 million in 2019 as a result of this legislation within Income tax provision (benefit) . During fiscal year 2019, the Company also changed its assertion with respect to historical unremitted foreign earnings, which resulted in a total tax benefit of $138 million, of which $67 million is related to the tax legislation benefit previously recorded, and is included as a component of Income tax provision (benefit) in fiscal 2019. The Company asserts indefinite reinvestment for all historical unremitted foreign earnings as of September 30, 2021. Unrecognized Tax Benefits The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized benefits will change due to one or more of the following events in the next twelve months: expiring statutes, audit activity, tax payments, other activity, or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate. (Millions of dollars) 2021 2020 2019 Balance at October 1 $ 620 $ 577 $ 601 Increase due to acquisitions 2 1 3 Increase due to current year tax positions 23 35 11 Increase due to prior year tax positions 6 76 6 Decreases due to prior year tax positions (4) (49) (39) Decrease due to settlements with tax authorities (183) (4) — Decrease due to lapse of statute of limitations (100) (16) (5) Balance at September 30 $ 364 $ 620 $ 577 Unrecognized tax benefits that would affect the effective tax rate if recognized $ 447 $ 719 $ 624 Upon the Company's acquisition of CareFusion in 2015, the Company became a party to a tax matters agreement with Cardinal Health resulting from Cardinal Health's spin-off of CareFusion in fiscal year 2010. Under the tax matters agreement, the Company is obligated to indemnify Cardinal Health for certain tax exposures and transaction taxes prior to CareFusion’s spin-off from Cardinal Health. The indemnification payable is approximately $119 million at September 30, 2021 and is included in Deferred Income Taxes and Other Liabilities on the consolidated balance sheet. The following were included for the years ended September 30 as a component of Income tax provision (benefit) on the consolidated statements of income. (Millions of dollars) 2021 2020 2019 Interest and penalties associated with unrecognized tax benefits $ 5 $ 1 $ 26 The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. The IRS has completed its audit for the BD legacy fiscal year 2014, BD combined company fiscal years 2015 and 2017 and CareFusion legacy fiscal years 2010 through short period 2015. With regard to Bard, all examinations have been completed through calendar year 2014, and calendar years 2015 through short period 2017 are currently under examination by the IRS. For the other major tax jurisdictions where the Company conducts business, tax years are generally open after 2012. Deferred Income Taxes Deferred income taxes at September 30 consisted of: 2021 2020 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 527 $ — $ 554 $ — Property and equipment — 410 — 361 Intangibles — 2,160 — 2,408 Loss and credit carryforwards 2,107 — 1,900 — Product recall and liability reserves 191 — 241 — Other 555 123 501 137 3,379 2,693 3,196 2,906 Valuation allowance (2,036) — (1,820) — Net (a) $ 1,343 $ 2,693 $ 1,376 $ 2,906 (a) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities on the consolidated balance sheets . Deferred tax assets and liabilities are netted on the balance sheet by separate tax jurisdictions. Deferred taxes have not been provided on undistributed earnings of foreign subsidiaries as of September 30, 2021 since the determination of the total amount of unrecognized deferred tax liability is not practicable. Generally, deferred tax assets have been established as a result of net operating losses and credit carryforwards with expiration dates from 2022 to an unlimited expiration date. Valuation allowances have been established as a result of an evaluation of the uncertainty associated with the realization of certain deferred tax assets on these losses and credit carryforwards. The valuation allowance at September 30, 2021 is primarily the result of foreign losses due to the Company’s global re-organization of its foreign entities and these generally have no expiration date. Valuation allowances are also maintained with respect to deferred tax assets for certain federal and state carryforwards that may not be realized and that principally expire in 2022. Tax Rate Reconciliation A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate was as follows: 2021 2020 2019 Federal statutory tax rate 21.0 % 21.0 % 21.0 % U.S. tax legislation (see discussion above) — — (4.3) State and local income taxes, net of federal tax benefit (1.9) (1.9) 0.1 Foreign income tax at rates other than 21% (8.1) (14.8) (6.6) Effect of foreign operations (0.1) 19.1 (5.5) Effect of Research Credits and FDII/Domestic Production Activities (1.6) (5.0) (3.3) Effect of share-based compensation 0.1 (4.5) (3.9) Effect of gain on divestitures — (4.5) (2.0) Effect of valuation allowance release (1.7) — — Other, net (1.0) 1.9 (0.3) Effective income tax rate 6.7 % 11.3 % (4.8) % The fluctuations in the Company’s reported tax rates are primarily due to the geographical mix of income attributable to foreign countries that have income tax rates that vary from the U.S. tax rate, and to the Act, the effects of which were recorded in fiscal year 2019. Tax Holidays and Payments The approximate tax impacts related to tax holidays in various countries in which the Company does business are provided below. The tax holidays expire at various dates through 2028. The Company’s income tax payments, net of refunds are also provided below. (Millions of dollars, except per share amounts) 2021 2020 2019 Tax impact related to tax holidays $ 248 $ 136 $ (43) Impact of tax holiday on diluted earnings per share 0.85 0.48 (0.16) Income tax payments, net of refunds 670 518 536

Leases, Codification Topic 842

Leases, Codification Topic 842	12 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Lessee, Operating Leases	Leases The Company leases real estate, vehicles and other equipment which are used in the Company’s manufacturing, administrative and research and development activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 6.9 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option. The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company’s short-term leases, as well as variable costs relating to the Company’s lease arrangements, are not material to its consolidated financial results. The implicit interest rates of the Company’s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The weighted-average incremental borrowing rate that has been applied to measure the Company’s lease liabilities is 2.2%. The Company’s lease costs recorded in its consolidated statements of income for the years ended September 30, 2021 and 2020 were $132 million and $131 million, respectively, under the new lease accounting standard. Rental expense for all operating leases amounted to $169 million in 2019 under the previous accounting standard. Cash payments arising from the Company’s lease arrangements are reflected on its consolidated statement of cash flows as outflows used for operating activities. The right-of-use assets and lease liabilities recognized on the Company’s consolidated balance sheet as of September 30, 2021 and 2020 were as follows: (Millions of dollars) 2021 2020 Right-of-use assets recorded in Other Assets $ 446 $ 418 Current lease liabilities recorded in Accrued expenses 126 106 Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities 344 336 The Company’s payments due under its operating leases are as follows: (Millions of dollars) 2022 $ 134 2023 96 2024 63 2025 45 2026 37 Thereafter 140 Total payments due 515 Less: imputed interest 45 Total $ 470 Sale-Leaseback Transactions During fiscal year 2021, the Company sold certain properties and concurrently entered into operating lease arrangements for each property, which met the requirements for sale-leaseback accounting. The Company recorded gross proceeds of $225 million related to the transactions and pre-tax gains of $158 million were recorded in Other operating expense. The lease agreements have initial lease terms between two six twelve

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information	Supplemental Financial Information Other Income (Expense), Net (Millions of dollars) 2021 2020 2019 Other investment gains, net (a) $ 57 $ 13 $ 18 Deferred compensation 43 24 6 Net pension and postretirement benefit cost (b) (1) 7 (2) Losses on undesignated foreign exchange derivatives, net (13) (17) (23) Losses on debt extinguishment (c) (178) (8) (59) Product related matters (2) (9) — Royalty and licensing income (d) — 17 64 Hurricane-related insurance proceeds — — 35 Other (3) (3) 4 Other (expense) income, net $ (97) $ 23 $ 43 (a) The amounts include gains (losses) recognized on changes to the fair value of certain equity investments. The amount in 2020 also includes a gain on the sale of an equity investment. (b) Represents all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost. (c) Represents losses recognized upon the extinguishment of certain senior notes, as further discussed in Note 15. (d) The amount in 2020 primarily represents licensing income. The amount in 2019 primarily represents the royalty income stream acquired in the Bard transaction, net of non-cash purchase accounting amortization. The royalty income stream was previously reported by Bard as revenues. Trade Receivables, Net The amounts recognized in 2021, 2020 and 2019 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Allowance for Total Balance at September 30, 2018 $ 75 $ 12 $ 86 Additions charged to costs and expenses 31 94 125 Deductions and other (31) (a) (92) (123) Balance at September 30, 2019 $ 75 $ 13 $ 88 Additions charged to costs and expenses 40 39 78 Deductions and other (35) (a) (38) (73) Balance at September 30, 2020 $ 80 $ 14 $ 94 Additions charged to costs and expenses 18 99 118 Deductions and other (22) (a) (92) (114) Balance at September 30, 2021 $ 76 $ 21 $ 97 (a) Accounts written off. Inventories Inventories at September 30 consisted of: (Millions of dollars) 2021 2020 Materials $ 641 $ 602 Work in process 402 335 Finished products 1,823 1,806 $ 2,866 $ 2,743 Property, Plant and Equipment, Net Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2021 2020 Land $ 137 $ 166 Buildings 3,264 3,082 Machinery, equipment and fixtures 9,301 8,454 Leasehold improvements 241 216 12,942 11,919 Less accumulated depreciation and amortization 6,549 5,996 $ 6,393 $ 5,923

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the "Company" or "BD") have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities.
Cash Equivalents	Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase.
Restricted Cash	Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters assumed in the acquisition of C.R. Bard, Inc. ("Bard"), which are further discussed in Note 5.
Trade and Financing Receivables	Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of expected credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable.
Inventories	Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis.
Property, Plant and Equipment	Property, Plant and EquipmentProperty, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four one
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill which arise from acquisitions of businesses. The Company currently reviews goodwill for impairment using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units generally represent one level below reporting segments. The Company’s review of goodwill for each reporting unit compares the fair value of the reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2021 indicated that all identified reporting units’ fair values exceeded their respective carrying values. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one
Foreign Currency Translation	Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss).
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized upon customer acceptance of these installed products. Revenue for certain service arrangements, including extended warranty and software maintenance contracts, is recognized ratably over the contract term. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. Variable consideration such as rebates, sales discounts and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices, and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Equipment lease transactions with customers are evaluated and classified as either operating or sales-type leases. Generally, these arrangements are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period defined within the customer agreement.
Contingencies	ContingenciesThe Company establishes accruals for future losses which are both probable and can be reasonably estimated (and in the case of environmental matters, without considering possible third-party recoveries). Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation in which the Company is a party. With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to the civil investigative demands (“CIDs”) served by the Department of Justice, discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.
Derivative Financial Instruments	Derivative Financial InstrumentsAll derivatives are recorded in the balance sheet at fair value and changes in fair value are recognized currently in earnings unless specific hedge accounting criteria are met. Any deferred gains or losses associated with derivative instruments are recognized in income in the period in which the underlying hedged transaction is recognized. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows for all other derivatives, including undesignated hedges, are classified in the same line item as the cash flows of the related hedged item, which is generally within operating or financing activities.
Income Taxes	Income Taxes The Company has reviewed its needs in the United States for possible repatriation of undistributed earnings of its foreign subsidiaries and continues to invest foreign subsidiaries earnings outside of the United States to fund foreign investments or meet foreign working capital and property, plant and equipment expenditure needs. As a result, the Company is permanently reinvested with respect to all of its historical foreign earnings as of September 30, 2021. Deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is not practicable because of the complexities associated with its hypothetical calculation. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters.
Earnings per Share	Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation.
Fair Value Measurement, Policy	Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Notes 9 and 14. Level 1 — Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2 — Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 — Inputs to the valuation methodology which are unobservable and significant to the fair value measurement.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.
New Accounting Principle Adopted and New Accounting Principles Not Yet Adopted	Accounting Changes New Accounting Principles Adopted In June 2016, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company’s adoption of this accounting standard on October 1, 2020, using the modified retrospective method, did not have a material impact on the Company's consolidated financial statements. On October 1, 2020, the Company retrospectively adopted an accounting standard update which added, removed and clarified disclosure requirements relating to defined benefit plans and other postretirement plans. The Company’s adoption of this update on October 1, 2020 did not materially impact its disclosures. See Note 9 for the Company’s defined pension plan and other benefit plan disclosures. In July 2018, the FASB issued accounting standard update (“ASU”) ASU 2018-09, "Codification Improvements", which, among other items, amended an illustrative example of a fair value hierarchy disclosure to indicate that a certain type of investment should not always be considered to be eligible to use the net asset value ("NAV") per share practical expedient. Also, it further clarified that an entity should evaluate whether a readily determinable fair value exists or whether its investments qualify for the NAV practical expedient. The Company early adopted this standard in the fourth quarter of fiscal year 2020 on a prospective basis, which is reflected in the fair value hierarchy classification of pension assets in Note 9, but does not change the fair value measurements of the investments. In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The Company early adopted this standard as of April 1, 2020 on a prospective basis. The adoption of this standard did not materially impact the Company's consolidated financial statements. In February 2016, the FASB issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019, and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 17. On October 1, 2018, the Company adopted Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") using the modified retrospective method. Under ASC 606, revenue is recognized upon the transfer of control of goods or services to customers and reflects the amount of consideration to which a reporting entity expects to be entitled in exchange for those goods or services. The Company assessed the impact of this new standard on its consolidated financial statements based upon a review of contracts that were not completed as of October 1, 2018. This accounting standard adoption, which is further discussed in Note 6, did not materially impact any line items of the Company's consolidated income statements and balance sheet. On October 1, 2018, the Company retrospectively adopted an accounting standard update which requires all components of net periodic pension and postretirement benefit costs to be disaggregated from the service cost component and to be presented on the income statement outside a subtotal of income from operations, if one is presented. Upon the Company's adoption of the accounting standard update, which did not have a material impact on its consolidated financial statements, all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other (expense) income, net on its consolidated income statements for all periods presented. On October 1, 2018, the Company adopted an accounting standard update which requires that the income tax effects of intercompany sales or transfers of assets, except those involving inventory, be recognized in the income statement as income tax expense (or benefit) in the period that the sale or transfer occurs. The Company adopted this accounting standard update, which did not have a material impact on its consolidated financial statements, using the modified retrospective method.
Revenue from Contract with Customer	Timing of Revenue Recognition The Company's revenues are primarily recognized when the customer obtains control of the product sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized when customer acceptance of these installed products has been confirmed. For certain service arrangements, including extended warranty and software maintenance contracts, revenue is recognized ratably over the contract term. The majority of revenues relating to extended warranty contracts associated with certain instruments and equipment is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over a longer period. Measurement of Revenues The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. The Company considers its shipping and handling costs to be costs of contract fulfillment and has made the accounting policy election to record these costs within Selling and administrative expense . Payment terms extended to the Company's customers are based upon commercially reasonable terms for the markets in which the Company's products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company's agreements with its end-user customers. Additional factors considered in the estimate of the Company's rebate liability include the quantification of inventory that is either in stock at or in transit to the Company's distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The Company’s rebate liability at September 30, 2021 and 2020 was $576 million and $526 million, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Additional disclosures relating to sales discounts and sales returns are provided in Note 18.
Fair Value of Financial Instruments, Policy	Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments
Concentration of Credit Risk	Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company

Commitment and Contingencies (P

Commitment and Contingencies (Policies)	12 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	ContingenciesThe Company establishes accruals for future losses which are both probable and can be reasonably estimated (and in the case of environmental matters, without considering possible third-party recoveries). Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation in which the Company is a party. With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to the civil investigative demands (“CIDs”) served by the Department of Justice, discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.

Leases, Codification Topic 842

Leases, Codification Topic 842 (Policies)	12 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Lessee, Leases	The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 6.9 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement.
Short-term Leases	The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Changes in Certain Components of Shareholders' Equity	Changes in certain components of shareholders’ equity were as follows: Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2018 $ 347 $ 16,179 $ 12,596 $ 22 (78,463) $ (6,243) Net income — — 1,233 — — — Cash dividends: Common ($3.08 per share) — — (832) — — — Preferred — — (152) — — — Common stock issued for share-based compensation and other plans, net — (170) (1) 1 2,155 53 Share-based compensation — 261 — — — — Common stock held in trusts, net (a) — — — — 48 — Effect of change in accounting principle (see Note 2) — — 68 — — — Balance at September 30, 2019 $ 347 $ 16,270 $ 12,913 $ 23 (76,260) $ (6,190) Net income — — 874 — — — Cash dividends: Common ($3.16 per share) — — (888) — — — Preferred — — (107) — — — Common stock issued for: Preferred shares converted to common shares 12 (9) — — — — Public equity offerings 6 2,909 — — — — Share-based compensation and other plans, net — (143) — — 1,597 52 Share-based compensation — 244 — — — — Common stock held in trusts, net (a) — — — — 41 — Balance at September 30, 2020 $ 365 $ 19,270 $ 12,791 $ 23 (74,623) $ (6,138) Net income — — 2,092 — — — Cash dividends: Common ($3.32 per share) — — (958) — — — Preferred — — (90) — — — Common stock issued for share-based compensation and other plans, net — (85) — — 1,068 15 Share-based compensation — 237 — — — — Common stock held in trusts, net (a) — — — — 33 — Repurchase of common stock — (150) — — (6,643) (1,600) Effect of change in accounting principle (see Note 2) — — (9) — — — Balance at September 30, 2021 $ 365 $ 19,272 $ 13,826 $ 23 (80,164) $ (7,723) (a) Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.
Accelerated Share Repurchases	The impacts of these accelerated share repurchase transactions were as follows: Execution Date Settlement Date Aggregate Common Stock Repurchased (millions of dollars) Initial Shares Delivered (in thousands) Additional Shares Delivered at Settlement (in thousands) (a) Total Shares Delivered (in thousands) Q3 2021 Q4 2021 $ 500 1,658 403 2,062 Q4 2021 Q1 2022 750 2,515 462 2,977 (a) Upon final settlement of each repurchase agreement and the forward sale contract, the Company’s receipt of additional shares was recorded as an increase to Common stock in treasury and an offsetting increase to Capital in excess of par value . The final settlement for the fourth quarter transaction amounted to $150 million.
Accumulated Other Comprehensive (Loss) Income	The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Benefit Plans Cash Flow Balance at September 30, 2018 $ (1,909) $ (1,162) $ (729) $ (17) Other comprehensive loss before reclassifications, net of taxes (427) (93) (325) (9) Amounts reclassified into income, net of 52 — 49 3 Balance at September 30, 2019 $ (2,283) $ (1,256) $ (1,005) $ (23) Other comprehensive loss before reclassifications, net of taxes (338) (161) (101) (76) Amounts reclassified into income, net of 74 — 66 8 Balance at September 30, 2020 $ (2,548) $ (1,416) $ (1,040) $ (91) Other comprehensive income before reclassifications, net of taxes 383 124 187 72 Amounts reclassified into income, net of 77 — 68 9 Balance at September 30, 2021 $ (2,088) $ (1,292) $ (784) $ (10)
Other Comprehensive Income (Loss), Tax	The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows: (Millions of dollars) 2021 2020 2019 Benefit Plans Income tax (provision) benefit for net gains (losses) recorded in other comprehensive income $ (42) $ 30 $ 91

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share	The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2021 2020 2019 Average common shares outstanding 289,288 278,971 269,943 Dilutive share equivalents from share-based plans (a) (b) 2,801 3,431 4,832 Average common and common equivalent shares outstanding — assuming dilution 292,089 282,402 274,775 (a) In 2021, 2020 and 2019, dilutive share equivalents associated with mandatory convertible preferred stock of 6 million, 9 million and 12 million, respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. The issuance of the convertible preferred stock is further discussed in Note 3. (b) In both 2021 and 2020, 1 million of certain share-based compensation awards were excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares. In 2019, no such awards were excluded from the diluted earnings per share calculation. Additional disclosures regarding the Company’s share-based compensation are provided in Note 8.

Segment Data (Tables)

Segment Data (Tables)	12 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas	Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. (Millions of dollars) 2021 2020 2019 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions $ 2,246 $ 1,812 $ 4,057 $ 1,972 $ 1,583 $ 3,555 $ 2,037 $ 1,811 $ 3,848 Medication Management Solutions 1,863 570 2,432 1,865 589 2,454 2,115 525 2,640 Diabetes Care 606 554 1,160 562 522 1,084 573 538 1,110 Pharmaceutical Systems 428 1,401 1,829 404 1,184 1,588 392 1,073 1,465 Total segment revenues $ 5,142 $ 4,336 $ 9,479 $ 4,802 $ 3,878 $ 8,680 $ 5,116 $ 3,947 $ 9,064 Life Sciences Integrated Diagnostic Solutions $ 2,477 $ 2,748 $ 5,225 $ 1,872 $ 1,659 $ 3,532 $ 1,446 $ 1,659 $ 3,106 Biosciences 503 802 1,305 465 678 1,143 485 709 1,194 Total segment revenues $ 2,980 $ 3,550 $ 6,530 $ 2,337 $ 2,337 $ 4,675 $ 1,931 $ 2,368 $ 4,300 Interventional Surgery $ 1,023 $ 274 $ 1,296 $ 891 $ 230 $ 1,121 $ 977 $ 264 $ 1,242 Peripheral Intervention 931 780 1,711 871 640 1,511 917 657 1,574 Urology and Critical Care 894 338 1,232 815 315 1,130 787 323 1,110 Total segment revenues $ 2,847 $ 1,392 $ 4,239 $ 2,577 $ 1,186 $ 3,762 $ 2,682 $ 1,244 $ 3,926 Total Company revenues $ 10,969 $ 9,279 $ 20,248 $ 9,716 $ 7,401 $ 17,117 $ 9,730 $ 7,560 $ 17,290
Financial Information for Company's Segments	(Millions of dollars) 2021 2020 2019 Income Before Income Taxes Medical (a) (b) (c) $ 2,583 $ 2,274 $ 2,824 Life Sciences (d) 2,391 1,405 1,248 Interventional (e) 933 724 903 Total Segment Operating Income 5,907 4,403 4,976 Acquisitions and other restructurings (185) (309) (480) Unallocated other operating expense, net (f) (238) (363) (579) Net interest expense (460) (521) (627) Other unallocated items (g) (2,783) (2,224) (2,115) Total Income Before Income Taxes $ 2,242 $ 985 $ 1,176 Capital Expenditures Medical $ 777 $ 477 $ 577 Life Sciences 297 192 230 Interventional 125 119 120 Corporate and All Other 32 22 30 Total Capital Expenditures $ 1,231 $ 810 $ 957 Depreciation and Amortization Medical $ 1,140 $ 1,104 $ 1,073 Life Sciences 352 286 284 Interventional 769 750 881 Corporate and All Other 12 14 14 Total Depreciation and Amortization $ 2,273 $ 2,154 $ 2,253 (a) The amounts in 2021 and 2020 include charges of $56 million and $244 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for BD Alaris TM infusion pumps in the Medication Management Solutions unit . (b) The amount in 2020 included $41 million of charges to Cost of products sold to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units. (c) The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform. (d) The amount in 2020 included charges of $57 million recorded to Cost of products sold to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units. (e) The amount in 2019 included a charge of $30 million recorded to Research and development expense to write down the carrying value of certain intangible assets in the Surgery unit. (f) The amounts in 2021, 2020 and 2019 include pre-tax charges of $361 million, $378 million and $914 million, respectively, related to certain product liability matters, which is further discussed in Note 5. The amount in 2021 also includes gains of $158 million on sale-leaseback transactions, which are further discussed in Note 17, and $35 million of costs incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business. The 2019 amount also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million, which is further discussed in Note 10. (g) Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment	Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. (Millions of dollars) 2021 2020 2019 Revenues United States $ 10,969 $ 9,716 $ 9,730 EMEA (a) 4,751 3,928 3,837 Greater Asia 3,272 2,568 2,726 Other (a) 1,255 905 997 $ 20,248 $ 17,117 $ 17,290 Long-Lived Assets United States $ 36,037 $ 36,468 $ 37,053 EMEA (a) 6,004 5,890 5,519 Greater Asia 1,662 1,521 1,328 Other (a) 860 753 824 Corporate 465 411 377 $ 45,029 $ 45,043 $ 45,101 (a) The amounts in fiscal years 2020 and 2019 reflect the reclassifications of $448 million and $478 million, respectively, of revenues and $55 million and $37 million, respectively, of long-lived assets in the Middle East and Africa.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Compensation Cost Relating to Share-Based Payments	The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2021 2020 2019 Cost of products sold $ 43 $ 40 $ 37 Selling and administrative expense 158 150 145 Research and development expense 36 34 32 Acquisitions and other restructurings 1 20 50 $ 238 $ 245 $ 265 Tax benefit associated with share-based compensation costs recognized $ 55 $ 57 $ 62
Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods	The fair value of awards was estimated on the date of grant using a lattice-based binomial option valuation model and these valuations were largely based upon the following weighted-average assumptions: 2021 2020 2019 Risk-free interest rate 0.68% 1.69% 3.05% Expected volatility 23.0% 19.0% 18.0% Expected dividend yield 1.46% 1.24% 1.27% Expected life 7.4 years 7.4 years 7.2 years Fair value derived $44.38 $48.82 $51.86
Summary of SARs Outstanding	A summary of SARs outstanding as of September 30, 2021 and changes during the year then ended is as follows: SARs (in Weighted Weighted Aggregate Balance at October 1 6,337 $ 167.17 Granted 1,097 227.83 Exercised (842) 128.13 Forfeited, canceled or expired (297) 237.47 Balance at September 30 6,295 $ 179.64 5.51 $ 424 Vested and expected to vest at September 30 6,113 $ 177.94 5.42 $ 421 Exercisable at September 30 4,471 $ 156.28 4.31 $ 403
Schedule Of Share Based Compensation, Summary of Stock Appreciation Rights Exercised	A summary of SARs exercised during 2021, 2020 and 2019 is as follows: (Millions of dollars) 2021 2020 2019 Total intrinsic value of SARs exercised $ 102 $ 212 $ 260 Total fair value of SARs vested $ 39 $ 46 $ 66
Summary of Performance-Based Restricted Stock Units Outstanding	A summary of restricted stock units outstanding as of September 30, 2021 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in Weighted Stock Units (in Weighted Balance at October 1 962 $ 244.42 1,697 $ 226.01 Granted 406 216.39 881 223.60 Distributed (39) 252.57 (601) 231.44 Forfeited or canceled (373) 245.86 (421) 231.29 Balance at September 30 957 (a) $ 231.63 1,556 $ 221.11 Expected to vest at September 30 339 (b) $ 227.92 1,478 $ 220.60 (a) Based on 200% of target payout for performance based restricted units and 100% of the performance based time-vested units. (b) Net of expected forfeited units and units in excess of the expected performance payout of 63 thousand and 555 thousand shares, respectively.
Schedule Of Share Based Compensation, Restricted Stock Units, Grant Date Fair Value of Units Granted	The weighted average grant date fair value of restricted stock units granted during the years 2021, 2020 and 2019 are as follows: Performance-Based Time-Vested 2021 2020 2019 2021 2020 2019 Weighted average grant date fair value of units granted $ 216.39 $ 245.06 $ 237.55 $ 223.60 $ 249.94 $ 235.50
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The total fair value of stock units vested during 2021, 2020 and 2019 was as follows: Performance-Based Time-Vested (Millions of dollars) 2021 2020 2019 2021 2020 2019 Total fair value of units vested $ 16 $ 27 $ 33 $ 203 $ 211 $ 254

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Sep. 30, 2021
Net Pension and Other Postretirement Cost	Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2021 2020 2019 Service cost $ 150 $ 153 $ 134 Interest cost 71 84 107 Expected return on plan assets (174) (188) (180) Amortization of prior service credit (16) (13) (13) Amortization of loss 97 97 78 Curtailment/settlement loss 9 4 10 Net pension cost $ 137 $ 137 $ 135 Net pension cost included in the preceding table that is attributable to international plans $ 41 $ 41 $ 32
Change in Benefit Obligation, Change in Fair Value of Plan Assets	The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2021 2020 Change in benefit obligation: Beginning obligation $ 3,953 $ 3,731 Service cost 150 153 Interest cost 71 84 Plan amendments (30) — Benefits paid (156) (186) Impact of acquisitions — 10 Actuarial (gain) loss (69) 104 Curtailments/settlements (49) (17) Other, includes translation 19 74 Benefit obligation at September 30 $ 3,889 $ 3,953 Change in fair value of plan assets: Beginning fair value $ 3,045 $ 2,926 Actual return on plan assets 317 222 Employer contribution 66 42 Benefits paid (156) (186) Impact of acquisitions — 7 Settlements (55) (17) Other, includes translation 5 51 Plan assets at September 30 $ 3,222 $ 3,045 Funded Status at September 30: Unfunded benefit obligation $ (667) $ (908) Amounts recognized in the Consolidated Balance Other $ 29 $ 16 Salaries, wages and related items (29) (23) Long-term Employee Benefit Obligations (667) (901) Net amount recognized $ (667) $ (908) Amounts recognized in Accumulated other Prior service credit $ 41 $ 31 Net actuarial loss (972) (1,281) Net amount recognized $ (931) $ (1,250)
Pension Plans with Accumulated Benefit Obligations	Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Projected Benefit (Millions of dollars) 2021 2020 2021 2020 Projected benefit obligation $ 3,475 $ 3,920 Accumulated benefit obligation $ 3,309 $ 3,703 Fair value of plan assets $ 2,712 $ 2,936 $ 2,780 $ 2,996
Weighted Average Assumptions Determining Pension Plan	The weighted average assumptions used in determining pension plan information were as follows: 2021 2020 2019 Net Cost Discount rate: U.S. plans (a) 2.80 % 3.21 % 4.26 % International plans 1.44 1.39 2.30 Expected return on plan assets: U.S. plans 6.25 7.25 7.25 International plans 4.92 5.05 4.98 Rate of compensation increase: U.S. plans 4.30 4.29 4.29 International plans 2.20 2.35 2.36 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 1.95 1.97 1.84 Benefit Obligation Discount rate: U.S. plans 2.89 2.80 3.21 International plans 1.75 1.44 1.39 Rate of compensation increase: U.S. plans 4.31 4.30 4.29 International plans 2.63 2.20 2.35 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 2.02 1.95 1.97
Expected Benefit Payments	Expected benefit payments are as follows: (Millions of dollars) Pension 2022 $ 242 2023 174 2024 178 2025 189 2026 206 2027-2031 1,113
Fair Value Measurements of U.S. Plan Assets	The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2021 and 2020. The categorization of fund investments is based upon the categorization of these funds’ underlying assets. Basis of fair value measurement (See Note 1) (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Level 1 Level 2 Level 3 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Fixed Income: Corporate bonds $ 679 $ 656 $ — $ — $ 297 $ 273 $ 382 $ 383 $ — $ — Government and agency-U.S. 184 95 — — 162 74 22 21 — — Government and agency-Foreign 46 40 — — — — 46 40 — — Other fixed income 141 141 — — — — 141 141 — — Equity securities 686 737 43 43 643 694 — — — — Cash and cash equivalents 168 147 — — 168 147 — — — — Other 286 291 152 151 135 141 — — — — Fair value of plan assets $ 2,189 $ 2,108 $ 195 $ 193 $ 1,405 $ 1,330 $ 590 $ 584 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator.
Fair Value Measurements of Foreign Plan Assets	The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2021 and 2020. Basis of fair value measurement (See Note 1) (Millions of dollars) Total International Investments Measured at Net Asset Value Level 1 Level 2 Level 3 (a) 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Fixed Income: Corporate bonds $ 55 $ 34 $ — $ — $ 37 $ 15 $ 18 $ 19 $ — $ — Government and agency-U.S. 13 3 — — 10 — 3 3 — — Government and agency-Foreign 264 212 — — 249 115 15 97 — — Other fixed income 121 102 — — 72 63 49 39 — — Equity securities 297 335 — — 297 335 — — — — Cash and cash equivalents 14 12 — — 14 12 — — — — Real estate 44 34 — — 2 — 31 24 11 10 Insurance contracts 118 131 — — — — — — 118 131 Other 107 72 — — 84 70 8 1 15 — Fair value of plan assets $ 1,033 $ 935 $ — $ — $ 765 $ 611 $ 124 $ 183 $ 145 $ 141 (a) Changes in the fair value of international pension assets measured using Level 3 inputs for the years ended September 30, 2021 and 2020 were immaterial.

Business Restructuring Charges

Business Restructuring Charges (Tables)	12 Months Ended
	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Summary of Restructuring Accrual Activity	Restructuring liability activity in 2021, 2020 and 2019 was as follows: Employee Termination Other Total (Millions of dollars) Bard Other Initiatives (a) Bard (b) Other Initiatives (a) Bard Other Initiatives (a) Balance at September 30, 2018 $ 33 $ 23 $ — $ 4 $ 33 $ 27 Charged to expense 23 29 95 33 118 62 Cash payments (34) (21) (5) (31) (39) (52) Non-cash settlements — — (89) (3) (89) (3) Balance at September 30, 2019 $ 22 $ 31 $ 1 $ 3 $ 23 $ 34 Charged to expense 7 13 42 33 49 46 Cash payments (14) (27) (18) (31) (32) (58) Non-cash settlements — — (24) (2) (24) (2) Balance at September 30, 2020 $ 15 $ 17 $ 1 $ 3 $ 16 $ 20 Charged to expense 1 13 2 34 3 47 Cash payments (5) (26) (2) (29) (7) (55) Non-cash settlements — — — (4) — (4) Other adjustments (1) — — — (1) — Balance at September 30, 2021 $ 10 $ 4 $ 1 $ 4 $ 11 $ 8 (a) Restructuring costs in 2021, 2020 and 2019 included expenses primarily related to simplification and other cost saving initiatives. (b) Expenses in 2020 and 2019 largely represented the costs associated with the conversion of certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date.

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	Intangible assets at September 30 consisted of: 2021 2020 (Millions of dollars) Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Amortized intangible assets Developed technology $ 14,399 $ (4,983) $ 9,417 $ 14,105 $ (3,959) $ 10,146 Customer relationships 4,658 (1,839) 2,818 4,616 (1,509) 3,107 Product rights 123 (83) 40 119 (73) 46 Trademarks 409 (137) 271 408 (120) 288 Patents and other 533 (342) 191 500 (320) 180 Amortized intangible assets $ 20,122 $ (7,385) $ 12,737 $ 19,748 $ (5,981) $ 13,767 Unamortized intangible assets Acquired in-process research and development $ 44 $ 44 Trademarks 2 2 Unamortized intangible assets $ 46 $ 46
Reconciliation of Goodwill by Business Segment	The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2019 $ 9,989 $ 772 $ 12,615 $ 23,376 Acquisitions (a) 10 58 49 117 Purchase price allocation adjustments — 1 4 5 Currency translation 44 7 71 122 Goodwill as of September 30, 2020 $ 10,044 $ 837 $ 12,739 $ 23,620 Acquisitions (a) 193 — 72 264 Purchase price allocation adjustments 4 — 1 6 Currency translation 15 (1) (2) 12 Goodwill as of September 30, 2021 $ 10,255 $ 836 $ 12,810 $ 23,901

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The notional amounts of the Company’s foreign currency-related derivative instruments as of September 30, 2021 and 2020 were as follows: (Millions of dollars) Hedge Designation 2021 2020 Foreign exchange contracts (a) Undesignated $ 2,735 $ 2,519 Foreign currency-denominated debt (b) Net investment hedges 2,543 1,522 Cross-currency swaps (c) Net investment hedges 1,958 2,971 (a) Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other (expense) income, net , during the years ending September 30, 2021, 2020 and 2019 are detailed in Note 18. (b) Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. (c) Represents cross-currency swaps which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amounts of the Company’s interest rate-related derivative instruments as of September 30, 2021 and 2020 were as follows: (Millions of dollars) Hedge Designation 2021 2020 Interest rate swaps (a) Fair value hedges $ 700 $ 375 Forward starting interest rate swaps (b) Cash flow hedges 1,000 1,500 (a) Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. In fiscal year 2021, certain interest rate swaps were terminated at an immaterial net gain, concurrently with the redemption of the 3.125% notes due November 8, 2021.
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges as of September 30, 2021, 2020 and 2019 were as follows: (Millions of dollars) 2021 2020 2019 Foreign currency-denominated debt $ 32 $ (106) $ 138 Cross-currency swaps (a) (21) (109) 73 Foreign currency forward contract (b) — — (9) (a) The amount in 2021 includes a loss of $35 million recognized on terminated cross-currency swaps. (b) The amount in 2019 represented a loss recognized on a forward contract which was entered into and terminated in fiscal year 2019.

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Cash and Cash Equivalents	The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at September 30, 2021 and 2020 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) 2021 2020 Cash and equivalents $ 2,283 $ 2,825 Restricted cash 109 92 Cash and equivalents and restricted cash $ 2,392 $ 2,917
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The fair values of the Company’s financial instruments are as follows: (Millions of dollars) Basis of fair value measurement (See Note 1) 2021 2020 Institutional money market accounts and ultra-short bond fund (a) Level 1 $ 200 $ 1,549 Current portion of long-term debt (b) Level 2 503 702 Long-term debt (b) Level 2 18,537 18,970 (a) These financial instruments are recorded within Cash and equivalents on the consolidated balance sheets. The institutional money market accounts permit daily redemption. Remaining cash and equivalents, excluding restricted cash, were $2.083 billion and $1.276 billion at September 30, 2021 and 2020, respectively. (b) Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments
Transfer of Financial Assets Accounted for as Sales	The amounts transferred and yet to be remitted under factoring arrangements in 2021 and 2020 are provided below. The Company’s transfers of trade receivables during fiscal year 2019 were not material to its consolidated financial results. (Millions of dollars) 2021 2020 Trade receivables transferred to third parties under factoring arrangements $ 1,302 $ 2,163 Amounts yet to be collected and remitted to the third parties 130 256

Debt (Tables)

Debt (Tables)	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Summary of Short-Term Debt	The carrying value of Short-term debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2021 2020 Current portion of long-term debt 0.174% Notes due June 4, 2021 (a) $ — $ 701 Floating Rate Notes due June 6, 2022 500 — Other — 5 Total short-term debt $ 500 $ 707 (a) All of the aggregate principal amount outstanding was retired during 2021, as further discussed below.
Summary of Long-Term Debt	The carrying value of Long-Term Debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2021 2020 3.125% Notes due November 8, 2021 (a) $ — $ 1,008 2.894% Notes due June 6, 2022 (a) — 1,797 Floating Rate Notes due June 6, 2022 — 499 1.000% Notes due December 15, 2022 579 584 3.300% Notes due March 1, 2023 (a) — 295 1.401% Notes due May 24, 2023 347 350 0.632% Notes due June 4, 2023 926 933 0.000% Notes due August 13, 2023 (b) 463 — 3.875% Notes due May 15, 2024 (a) 146 180 3.363% Notes due June 6, 2024 (a) 994 1,742 3.734% Notes due December 15, 2024 (a) 873 1,370 3.020% Notes due May 24, 2025 336 320 0.034% Notes due August 13, 2025 (b) 577 — 1.208% Notes due June 4, 2026 693 699 6.700% Notes due December 1, 2026 168 172 1.900% Notes due December 15, 2026 577 582 3.700% Notes due June 6, 2027 1,716 1,715 7.000% Debentures due August 1, 2027 174 175 6.700% Debentures due August 1, 2028 173 174 0.334% Notes due August 13, 2028 (b) 1,037 — 2.823% Notes due May 20, 2030 744 743 1.957% Notes due February 11, 2031 (b) 992 — 1.213% Notes due February 12, 2036 (b) 690 — 6.000% Notes due May 15, 2039 246 246 5.000% Notes due November 12, 2040 124 124 1.336% Notes due August 13, 2041 (b) 1,034 — 4.875% Notes due May 15, 2044 246 247 4.685% Notes due December 15, 2044 1,033 1,044 4.669% Notes due June 6, 2047 1,481 1,485 3.794% Notes due May 20, 2050 742 742 Total Long-Term Debt $ 17,110 $ 17,224 (a) All or a portion of the aggregate principal amount outstanding was retired during 2021, as further discussed below. (b) Represents notes issued during 2021, as further discussed below.
Schedule of Debt Issuances	The Company issued the following U.S. dollar-denominated debt during fiscal years 2021 and 2020: Interest rate and maturity Period issued Amount issued (millions of dollars) Use of proceeds 1.957% notes due February 11, 2031 Second quarter 2021 $ 1,000 Retirement of 3.125% notes due November 8, 2021 2.823% notes due May 20, 2030 Third quarter 2020 750 Retirements of 2.404% notes due June 5, 2020 and 3.250% notes due November 12, 2020 3.794% notes due May 20, 2050 Third quarter 2020 750 Retirements of 2.404% notes due June 5, 2020 and 3.250% notes due November 12, 2020 The Company issued the following Euro-denominated debt during fiscal year 2021: Interest rate and maturity Period issued Amount issued (millions of Euros) Amount issued (millions of dollars) Use of proceeds 0.000% notes due August 13, 2023 Fourth quarter 2021 € 400 $ 470 Fourth quarter 2021 retirements detailed below 0.034% notes due August 13, 2025 Fourth quarter 2021 500 587 Fourth quarter 2021 retirements detailed below Interest rate and maturity Period issued Amount issued (millions of Euros) Amount issued (millions of dollars) Use of proceeds 0.334% notes due August 13, 2028 Fourth quarter 2021 € 900 $ 1,055 Fourth quarter 2021 retirements detailed below 1.336% notes due August 13, 2041 Fourth quarter 2021 900 1,055 Fourth quarter 2021 retirements detailed below 1.213% notes due February 12, 2036 Second quarter 2021 600 728 Retirement of 0.174% notes due June 4, 2021
Schedule of Extinguishment of Debt	The Company’s retirements of debt in fiscal year 2021 included the following: (millions of dollars) Principal, interest rate and maturity Period of retirement Carrying value Market price of retirement (a) Loss recognized to Other (expense) income, net (b) $1.535 billion of 2.894% notes due June 6, 2022 Fourth quarter 2021 $ 1,534 $ 1,566 $ 32 $294 million of 3.300% notes due March 1, 2023 Fourth quarter 2021 295 307 12 $33 million of 3.875% notes due May 15, 2024 Fourth quarter 2021 33 35 2 $500 million of 3.734% notes due December 15, 2024 Fourth quarter 2021 499 546 48 $752 million of 3.363% notes due June 6, 2024 Fourth quarter 2021 750 808 58 $1.0 billion of 3.125% notes due November 8, 2021 Second quarter 2021 1,005 1,019 14 600 million Euros ($728 million) of 0.174% notes due June 4, 2021 Second quarter 2021 728 730 1 $265 million of 2.894% notes due June 6, 2022 First quarter 2021 265 275 10 (a) Included accrued interest, related premiums, fees and expenses. (b) All debt retirements in fiscal year 2021 were accounted for as early debt extinguishments. The Company’s retirements of debt in fiscal year 2020 included the following: (millions of dollars) Principal, interest rate and maturity Period of retirement Carrying value Market price of retirement (a) Loss recognized to Other (expense) income, net $200 million of 3.250% notes due November 12, 2020 and $750 million of floating rate notes due December 29, 2020 (b) Fourth quarter 2020 $ 950 $ 951 $ 1 $1.0 billion of 2.404% notes due June 5, 2020 Third quarter 2020 1,000 1,000 — $500 million of 3.250% notes due November 12, 2020 (b) Third quarter 2020 500 506 6 (a) Included accrued interest, related premiums, fees and expenses. (b) Debt retirement was accounted for as an early debt extinguishment.
Summary of Interest Costs and Payments	A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2021 2020 2019 Charged to operations $ 469 $ 528 $ 639 Capitalized 44 43 44 Total interest costs $ 512 $ 571 $ 683 Interest paid, net of amounts capitalized $ 474 $ 515 $ 658

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Provision for Income Taxes from Continuing Operations	The provision (benefit) for income taxes the years ended September 30 consisted of: (Millions of dollars) 2021 2020 2019 Current: Federal $ 102 $ (50) $ 235 State and local, including Puerto Rico 46 47 41 Foreign 290 400 300 $ 438 $ 397 $ 576 Deferred: Domestic $ (286) $ (184) $ (577) Foreign (2) (101) (56) (288) (286) (633) Income tax provision (benefit) $ 150 $ 111 $ (57) The following were included for the years ended September 30 as a component of Income tax provision (benefit) on the consolidated statements of income. (Millions of dollars) 2021 2020 2019 Interest and penalties associated with unrecognized tax benefits $ 5 $ 1 $ 26
Components of Income from Continuing Operations Before Income Taxes	The components of Income Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2021 2020 2019 Domestic, including Puerto Rico $ 133 $ (489) $ 799 Foreign 2,109 1,474 377 Income Before Income Taxes $ 2,242 $ 985 $ 1,176
Summary of Gross Amounts of Unrecognized Tax Benefits	The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized benefits will change due to one or more of the following events in the next twelve months: expiring statutes, audit activity, tax payments, other activity, or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate. (Millions of dollars) 2021 2020 2019 Balance at October 1 $ 620 $ 577 $ 601 Increase due to acquisitions 2 1 3 Increase due to current year tax positions 23 35 11 Increase due to prior year tax positions 6 76 6 Decreases due to prior year tax positions (4) (49) (39) Decrease due to settlements with tax authorities (183) (4) — Decrease due to lapse of statute of limitations (100) (16) (5) Balance at September 30 $ 364 $ 620 $ 577 Unrecognized tax benefits that would affect the effective tax rate if recognized $ 447 $ 719 $ 624
Deferred Income Taxes	Deferred income taxes at September 30 consisted of: 2021 2020 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 527 $ — $ 554 $ — Property and equipment — 410 — 361 Intangibles — 2,160 — 2,408 Loss and credit carryforwards 2,107 — 1,900 — Product recall and liability reserves 191 — 241 — Other 555 123 501 137 3,379 2,693 3,196 2,906 Valuation allowance (2,036) — (1,820) — Net (a) $ 1,343 $ 2,693 $ 1,376 $ 2,906 (a) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities on the consolidated balance sheets .
Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate	A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate was as follows: 2021 2020 2019 Federal statutory tax rate 21.0 % 21.0 % 21.0 % U.S. tax legislation (see discussion above) — — (4.3) State and local income taxes, net of federal tax benefit (1.9) (1.9) 0.1 Foreign income tax at rates other than 21% (8.1) (14.8) (6.6) Effect of foreign operations (0.1) 19.1 (5.5) Effect of Research Credits and FDII/Domestic Production Activities (1.6) (5.0) (3.3) Effect of share-based compensation 0.1 (4.5) (3.9) Effect of gain on divestitures — (4.5) (2.0) Effect of valuation allowance release (1.7) — — Other, net (1.0) 1.9 (0.3) Effective income tax rate 6.7 % 11.3 % (4.8) %
Summary of Income Tax Holiday	The approximate tax impacts related to tax holidays in various countries in which the Company does business are provided below. The tax holidays expire at various dates through 2028. The Company’s income tax payments, net of refunds are also provided below. (Millions of dollars, except per share amounts) 2021 2020 2019 Tax impact related to tax holidays $ 248 $ 136 $ (43) Impact of tax holiday on diluted earnings per share 0.85 0.48 (0.16) Income tax payments, net of refunds 670 518 536

Leases, Codification Topic 84_2

Leases, Codification Topic 842 (Tables)	12 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Supplemental Balance Sheet Information Related to Leases	The right-of-use assets and lease liabilities recognized on the Company’s consolidated balance sheet as of September 30, 2021 and 2020 were as follows: (Millions of dollars) 2021 2020 Right-of-use assets recorded in Other Assets $ 446 $ 418 Current lease liabilities recorded in Accrued expenses 126 106 Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities 344 336
Lessee, Operating Lease, Liability, Maturity	The Company’s payments due under its operating leases are as follows: (Millions of dollars) 2022 $ 134 2023 96 2024 63 2025 45 2026 37 Thereafter 140 Total payments due 515 Less: imputed interest 45 Total $ 470

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Nonoperating Income (Expense)	Other Income (Expense), Net (Millions of dollars) 2021 2020 2019 Other investment gains, net (a) $ 57 $ 13 $ 18 Deferred compensation 43 24 6 Net pension and postretirement benefit cost (b) (1) 7 (2) Losses on undesignated foreign exchange derivatives, net (13) (17) (23) Losses on debt extinguishment (c) (178) (8) (59) Product related matters (2) (9) — Royalty and licensing income (d) — 17 64 Hurricane-related insurance proceeds — — 35 Other (3) (3) 4 Other (expense) income, net $ (97) $ 23 $ 43 (a) The amounts include gains (losses) recognized on changes to the fair value of certain equity investments. The amount in 2020 also includes a gain on the sale of an equity investment. (b) Represents all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost. (c) Represents losses recognized upon the extinguishment of certain senior notes, as further discussed in Note 15. (d) The amount in 2020 primarily represents licensing income. The amount in 2019 primarily represents the royalty income stream acquired in the Bard transaction, net of non-cash purchase accounting amortization. The royalty income stream was previously reported by Bard as revenues.
Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts	The amounts recognized in 2021, 2020 and 2019 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Allowance for Total Balance at September 30, 2018 $ 75 $ 12 $ 86 Additions charged to costs and expenses 31 94 125 Deductions and other (31) (a) (92) (123) Balance at September 30, 2019 $ 75 $ 13 $ 88 Additions charged to costs and expenses 40 39 78 Deductions and other (35) (a) (38) (73) Balance at September 30, 2020 $ 80 $ 14 $ 94 Additions charged to costs and expenses 18 99 118 Deductions and other (22) (a) (92) (114) Balance at September 30, 2021 $ 76 $ 21 $ 97 (a) Accounts written off.
Inventories	Inventories at September 30 consisted of: (Millions of dollars) 2021 2020 Materials $ 641 $ 602 Work in process 402 335 Finished products 1,823 1,806 $ 2,866 $ 2,743
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2021 2020 Land $ 137 $ 166 Buildings 3,264 3,082 Machinery, equipment and fixtures 9,301 8,454 Leasehold improvements 241 216 12,942 11,919 Less accumulated depreciation and amortization 6,549 5,996 $ 6,393 $ 5,923

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Summary of Significant Accounting Policies [Line Items]
Depreciation and amortization expense	$ 731	$ 646	$ 633
Selling and administrative expense	4,867	4,325	4,332
Shipping and Handling
Summary of Significant Accounting Policies [Line Items]
Selling and administrative expense	$ 656	$ 551	$ 511
Minimum
Summary of Significant Accounting Policies [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Minimum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Minimum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	10 years
Minimum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	1 year
Minimum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years
Minimum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	4 years
Minimum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	1 year
Maximum
Summary of Significant Accounting Policies [Line Items]
Maturity period of short-term investments at the time of purchase	1 year
Maximum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	20 years
Maximum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Maximum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	40 years
Maximum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	45 years
Maximum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	13 years
Maximum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years

Shareholders' Equity - Changes

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 23,765
Beginning balance (shares)	(74,622,657)
Net Income	$ 2,092	$ 874	$ 1,233
Ending balance	$ 23,677	$ 23,765
Ending balance (shares)	(80,163,949)	(74,622,657)
Common Stock  Issued at Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 365	$ 347	347
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments		12
Stock Issued During Period, Value, New Issues		6
Ending balance	365	365	347
Capital in Excess of Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	19,270	16,270	16,179
Common stock issued for share-based compensation and other plans, net	(85)	(143)	(170)
Share-based compensation	237	244	261
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments		(9)
Stock Issued During Period, Value, New Issues		2,909
Treasury Stock, Value, Acquired, Cost Method	(150)
Ending balance	19,272	19,270	16,270
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	12,791	12,913	12,596
Net Income	2,092	874	1,233
Cash dividends, common	(958)	(888)	(832)
Dividends, Preferred Stock	(90)	(107)	(152)
Common stock issued for share-based compensation and other plans, net			(1)
Ending balance	13,826	12,791	12,913
Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Other	(9)		68
Deferred Compensation
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	23	23	22
Common stock issued for share-based compensation and other plans, net			1
Ending balance	23	23	23
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ (6,138)	$ (6,190)	$ (6,243)
Beginning balance (shares)	(74,623,000)	(76,260,000)	(78,463,000)
Common stock issued for share-based compensation and other plans, net	$ 15	$ 52	$ 53
Share-based compensation plans, net (shares)	1,068,000	1,597,000	2,155,000
Common stock held in trusts, net (shares)	33,000	41,000	48,000
Treasury Stock, Value, Acquired, Cost Method	$ (1,600)
Treasury Stock, Shares, Acquired	(6,643,000)
Ending balance	$ (7,723)	$ (6,138)	$ (6,190)
Ending balance (shares)	(80,164,000)	(74,623,000)	(76,260,000)

Shareholders' Equity - Change_2

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Detail II) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Common stock dividend per share (USD per share)	$ 3.32	$ 3.16	$ 3.08

Shareholders' Equity - Accumula

Shareholders' Equity - Accumulated Other Comprehensive (Loss) Income (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	$ (2,548)	$ (2,548)	$ (2,283)	$ (1,909)
Other comprehensive loss before reclassifications, net of taxes		383	(338)	(427)
Amounts reclassified into income, net of taxes		77	74	52
Accumulated other comprehensive (loss) income, ending balance		(2,088)	(2,548)	(2,283)
Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(1,416)	(1,416)	(1,256)	(1,162)
Other comprehensive loss before reclassifications, net of taxes		124	(161)	(93)
Amounts reclassified into income, net of taxes		0	0	0
Accumulated other comprehensive (loss) income, ending balance		(1,292)	(1,416)	(1,256)
Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(1,040)	(1,040)	(1,005)	(729)
Other comprehensive loss before reclassifications, net of taxes	24	187	(101)	(325)
Amounts reclassified into income, net of taxes		68	66	49
Accumulated other comprehensive (loss) income, ending balance		(784)	(1,040)	(1,005)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	$ (91)	(91)	(23)	(17)
Other comprehensive loss before reclassifications, net of taxes		72	(76)	(9)
Amounts reclassified into income, net of taxes		9	8	3
Accumulated other comprehensive (loss) income, ending balance		$ (10)	$ (91)	$ (23)

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) $ / shares in Units, shares in Thousands	1 Months Ended			3 Months Ended			12 Months Ended
	Oct. 31, 2021USD ($)shares	Jul. 31, 2021shares	May 31, 2020USD ($)shares	Sep. 30, 2021USD ($)transaction$ / sharesshares	Jun. 30, 2021transactionshares	Dec. 31, 2020USD ($)	Sep. 30, 2021USD ($)lawsuittransaction$ / sharesshares	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Nov. 04, 2021shares	May 01, 2020shares
Class of Stock [Line Items]
Stock Repurchase Program, Number of Shares Authorized to be Repurchased				10,000			10,000
Other comprehensive loss before reclassifications, net of taxes | $							$ 383,000,000	$ (338,000,000)	$ (427,000,000)
Number of Accelerated Share Repurchase Agreements | lawsuit							2
Subsequent Event
Class of Stock [Line Items]
Stock Repurchase Program, Number of Shares Authorized to be Repurchased										10,000
Treasury Stock
Class of Stock [Line Items]
Treasury Stock, Shares, Acquired							6,643
Treasury Stock, Value, Acquired, Cost Method | $							$ 1,600,000,000
Benefit Plans
Class of Stock [Line Items]
Other comprehensive loss before reclassifications, net of taxes | $						$ 24,000,000	$ 187,000,000	$ (101,000,000)	$ (325,000,000)
Open Market Repurchases
Class of Stock [Line Items]
Treasury Stock, Shares, Acquired							2,066
Open Market Repurchases | Treasury Stock
Class of Stock [Line Items]
Treasury Stock, Value, Acquired, Cost Method | $							$ 500,000,000
Accelerated Share Repurchase Program
Class of Stock [Line Items]
Number of Transactions | transaction				2	2		2
Treasury Stock, Shares, Acquired		403		2,515	1,658
Accelerated Share Repurchase Program | Subsequent Event
Class of Stock [Line Items]
Treasury Stock, Shares, Acquired	462
Accelerated Share Repurchase Program | Treasury Stock | Subsequent Event
Class of Stock [Line Items]
Treasury Stock, Value, Acquired, Cost Method | $	$ 150,000,000
Minimum
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion				5,200			5,200
Maximum
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion				6,200			6,200
Common Stock  Issued at Par Value
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion											11,703
Stock Issued During Period, Shares, New Issues			6,250
Gross Proceeds from Issuance of Equity | $			$ 1,500,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock | $			$ 1,459,000,000
Convertible Preferred Stock
Class of Stock [Line Items]
Preferred Stock, Depositary Share Ownership Interest, Percentage			5.00%
Preferred Stock, Shares Outstanding											2,475
Stock Issued During Period, Shares, New Issues			1,500
Gross Proceeds from Issuance of Equity | $			$ 1,500,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock | $			$ 1,459,000,000
Depositary Share Liquidation | $				$ 50			$ 50
Preferred Stock, Liquidation Preference Per Share | $ / shares				$ 1,000			$ 1,000
Preferred Stock, Dividend Rate, Percentage							6.00%

Shareholders' Equity - Other Co

Shareholders' Equity - Other Comprehensive Income (Loss), Tax (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Income tax (provision) benefit for net gains (losses) recorded in other comprehensive income	$ (42)	$ 30	$ 91

Shareholders' Equity - Accelera

Shareholders' Equity - Accelerated Share Repurchases (Detail) - USD ($) shares in Thousands, $ in Millions	1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 31, 2021	Jul. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2021
Capital in Excess of Par Value
Accelerated Share Repurchases [Line Items]
Treasury Stock, Value, Acquired, Cost Method					$ 150
Treasury Stock
Accelerated Share Repurchases [Line Items]
Treasury Stock, Shares, Acquired					6,643
Treasury Stock, Value, Acquired, Cost Method					$ 1,600
Accelerated Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Treasury Stock, Shares, Acquired		403	2,515	1,658
Total Shares to be Delivered Under Accelerated Share Repurchase Program			2,977	2,062
Stock Repurchase Program, Authorized Amount			$ 750	$ 500	$ 750
Accelerated Share Repurchase Program | Subsequent Event
Accelerated Share Repurchases [Line Items]
Treasury Stock, Shares, Acquired	462
Accelerated Share Repurchase Program | Capital in Excess of Par Value | Subsequent Event
Accelerated Share Repurchases [Line Items]
Treasury Stock, Value, Acquired, Cost Method	$ 150
Accelerated Share Repurchase Program | Treasury Stock | Subsequent Event
Accelerated Share Repurchases [Line Items]
Treasury Stock, Value, Acquired, Cost Method	$ 150

Earnings per Share - Weighted A

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Average common shares outstanding (shares)	289,288	278,971	269,943
Dilutive share equivalents from share-based plans (shares)	2,801	3,431	4,832
Average common and common equivalent shares outstanding - assuming dilution (shares)	292,089	282,402	274,775

Earnings per Share - Weighted_2

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share Footnotes (Details) - shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,000,000	1,000,000	0
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,000,000	9,000,000	12,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	1 Months Ended		12 Months Ended
	Jul. 31, 2021lawsuit	Apr. 30, 2018USD ($)	Sep. 30, 2021USD ($)lawsuit	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)
Loss Contingencies [Line Items]
Aggregate future purchase commitments			$ 1,670
Number of Days to Replead | lawsuit			45
Product Liability Accrual, Period Expense			$ 361
Loss Contingency Accrual			2,500	$ 2,500
QualifiedSettlementFunds			106	92
Loss Contingency, Receivable			93	139
Gwinnett County, Georgia
Loss Contingencies [Line Items]
Number of EtO Sterilization Lawsuits | lawsuit	160
Other Operating Income (Expense)
Loss Contingencies [Line Items]
Product Liability Accrual, Period Expense			$ 361	$ 378	$ 914
HerniaProductClaims
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number			25,030
WomensHealthProductClaims
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number			405
ClaimsLackingSufficientInformation			830
PaymentstoSupplier			$ 161
NumberOfClaimsInSettlementAgreement			15,295
Damages awarded		$ 68
WomensHealthProductClaims | Compensatory
Loss Contingencies [Line Items]
Damages awarded		33
WomensHealthProductClaims | Punitive
Loss Contingencies [Line Items]
Damages awarded		$ 35
FilterProductClaims
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number			275
Loss Contingency, Claims Settled, Number			9,505

Revenues Revenues - Additional

Revenues Revenues - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Rebate liability	$ 576	$ 526
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Products and/or Services
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 2,100
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | Consumables
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 2,500

Segment Data - Additional Infor

Segment Data - Additional Information (Detail) $ in Millions	12 Months Ended
	Sep. 30, 2021USD ($)customersegment	Sep. 30, 2020USD ($)customer	Sep. 30, 2019USD ($)customer
Segment Reporting Information [Line Items]
Number of principal business segments (segments) | segment	3
Number of customers accounted for 10% or more of revenues (customers) | customer	0	0	0
Revenues	$ 20,248	$ 17,117	$ 17,290
Product Liability Accrual, Period Expense	361
Gain (Loss) on Disposition of Business	0	0	336
United States
Segment Reporting Information [Line Items]
Revenues	10,969	9,716	9,730
Non-US
Segment Reporting Information [Line Items]
Revenues	9,279	7,401	7,560
Advanced Bioprocessing
Segment Reporting Information [Line Items]
Gain (Loss) on Disposition of Business			336
Medical
Segment Reporting Information [Line Items]
Inventory Recall Expense	56	244	75
Asset Impairment Charges		41
Life Sciences
Segment Reporting Information [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)		57
Interventional
Segment Reporting Information [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)			30
Other Operating Income (Expense)
Segment Reporting Information [Line Items]
Product Liability Accrual, Period Expense	361	$ 378	$ 914
Sale and Leaseback Transaction, Gain (Loss), Net	158
Separation and Related Costs	$ 35

Segment Data Segment Data - Rev

Segment Data Segment Data - Revenues by Geographic Areas (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenues	$ 20,248	$ 17,117	$ 17,290
Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	9,479	8,680	9,064
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	6,530	4,675	4,300
Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	4,239	3,762	3,926
United States
Segment Reporting Information [Line Items]
Revenues	10,969	9,716	9,730
United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	5,142	4,802	5,116
United States | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	2,980	2,337	1,931
United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	2,847	2,577	2,682
Non-US
Segment Reporting Information [Line Items]
Revenues	9,279	7,401	7,560
Non-US | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	4,336	3,878	3,947
Non-US | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	3,550	2,337	2,368
Non-US | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,392	1,186	1,244
Medication Delivery Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	4,057	3,555	3,848
Medication Delivery Solutions | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	2,246	1,972	2,037
Medication Delivery Solutions | Non-US | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	1,812	1,583	1,811
Medication Management Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	2,432	2,454	2,640
Medication Management Solutions | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	1,863	1,865	2,115
Medication Management Solutions | Non-US | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	570	589	525
Diabetes Care | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	1,160	1,084	1,110
Diabetes Care | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	606	562	573
Diabetes Care | Non-US | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	554	522	538
Pharmaceutical Systems | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	1,829	1,588	1,465
Pharmaceutical Systems | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	428	404	392
Pharmaceutical Systems | Non-US | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	1,401	1,184	1,073
Integrated Diagnostic Solutions | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	5,225	3,532	3,106
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	2,477	1,872	1,446
Integrated Diagnostic Solutions | Non-US | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	2,748	1,659	1,659
Biosciences | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	1,305	1,143	1,194
Biosciences | United States | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	503	465	485
Biosciences | Non-US | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	802	678	709
Surgery | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,296	1,121	1,242
Surgery | United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,023	891	977
Surgery | Non-US | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	274	230	264
Peripheral Intervention | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,711	1,511	1,574
Peripheral Intervention | United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	931	871	917
Peripheral Intervention | Non-US | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	780	640	657
Urology and Critical Care | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,232	1,130	1,110
Urology and Critical Care | United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	894	815	787
Urology and Critical Care | Non-US | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	$ 338	$ 315	$ 323

Segment Data - Financial Inform

Segment Data - Financial Information for Company's Segments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Acquisitions and other restructurings	$ 185	$ 309	$ 480
Other Operating Income (Expense), Net	(238)	(363)	(654)
Total Capital Expenditures	1,231	810	957
Total Depreciation and Amortization	2,273	2,154	2,253
Operating Segments
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	5,907	4,403	4,976
Operating Segments | Medical
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	2,583	2,274	2,824
Total Capital Expenditures	777	477	577
Total Depreciation and Amortization	1,140	1,104	1,073
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	2,391	1,405	1,248
Total Capital Expenditures	297	192	230
Total Depreciation and Amortization	352	286	284
Operating Segments | Interventional
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	933	724	903
Total Capital Expenditures	125	119	120
Total Depreciation and Amortization	769	750	881
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisitions and other restructurings	185	309	480
Other Operating Income (Expense), Net	(238)	(363)	(579)
Net interest expense	(460)	(521)	(627)
Corporate and All Other
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	(2,783)	(2,224)	(2,115)
Total Capital Expenditures	32	22	30
Total Depreciation and Amortization	$ 12	$ 14	$ 14

Segment Data - Revenues to Unaf

Segment Data - Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 20,248	$ 17,117	$ 17,290
Long-Lived Assets	45,029	45,043	45,101
Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	465	411	377
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	10,969	9,716	9,730
Long-Lived Assets	36,037	36,468	37,053
EMEA (a)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	4,751	3,928	3,837
Long-Lived Assets	6,004	5,890	5,519
Greater Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	3,272	2,568	2,726
Long-Lived Assets	1,662	1,521	1,328
Other (a)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1,255	905	997
Long-Lived Assets	$ 860	753	824
Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		448	478
Long-Lived Assets		$ 55	$ 37

Share-Based Compensation - Comp

Share-Based Compensation - Compensation Cost Relating to Share-Based Payments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	$ 238	$ 245	$ 265
Income tax benefit recognized	55	57	62
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	43	40	37
Selling and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	158	150	145
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	36	34	32
Acquisitions and other restructurings
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	$ 1	$ 20	$ 50

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 238	$ 245	$ 265
SARs vesting period	4 years
SARs terms of award	10 years
Stock Issued under SARs exercised (in shares)	400,000
Percentage of Target Payout on which Performance Based Time-vested Restricted Stock Units are Based	100.00%
Percentage Of Target Payout On Which Performance Based Restricted Stock Units Are Based	200.00%
Unrecognized compensation expense for all non-vested share-based awards	$ 247
Weighted-average remaining life non-vested share-based awards	1 year 11 months 8 days
Shares were authorized for future grants	8,600,000
Shares issuable under deferred compensation plan	259,000
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferral plan, shares held in trust	93,000
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	3 years
Performance period	3 years
Weighted average remaining vesting term	1 year 3 months 7 days
Performance-Based Restricted Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	0.00%
Performance-Based Restricted Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	200.00%
Time-Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	3 years
Weighted average remaining vesting term	10 months 20 days
Time-Vested Restricted Stock Units | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	1 year
Acquisitions and other restructurings
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 1	20	50
Acquisitions and other restructurings | CR Bard Inc
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense		$ 16	$ 40

Share-Based Compensation - Assu

Share-Based Compensation - Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods (Detail) - Stock Appreciation Rights (SARs) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.68%	1.69%	3.05%
Expected volatility	23.00%	19.00%	18.00%
Expected dividend yield	1.46%	1.24%	1.27%
Expected life	7 years 4 months 24 days	7 years 4 months 24 days	7 years 2 months 12 days
Fair value derived (USD per share)	$ 44.38	$ 48.82	$ 51.86

Share-Based Compensation - Summ

Share-Based Compensation - Summary of SARs Outstanding (Detail) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
SARs, beginning balance (shares) | shares	6,337
SARs, granted (shares) | shares	1,097
SARs, exercised (shares) | shares	(842)
SARs, forfeited, canceled or expired (shares) | shares	(297)
SARs, ending balance (shares) | shares	6,295
SARs, Vested and expected to vest at ending balance (shares) | shares	6,113
SARs, Exercisable at ending balance (shares) | shares	4,471
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
SARs, weighted average exercise price, beginning balance (USD per share) | $ / shares	$ 167.17
SARs, weighted average exercise price, granted (USD per share) | $ / shares	227.83
SARs, weighted average exercise price, exercised (USD per share) | $ / shares	128.13
SARs, weighted average exercise price, forfeited, canceled or expired (USD per share) | $ / shares	237.47
SARs, weighted average exercise price, ending balance (USD per share) | $ / shares	179.64
SARs, weighted average exercise price, vested and expected to vest (USD per share) | $ / shares	177.94
SARs, weighted average exercise price, exercisable (USD per share) | $ / shares	$ 156.28
SARs, weighted average remaining contractual term	5 years 6 months 3 days
SARs, weighted average remaining contractual term, vested and expected to vest	5 years 5 months 1 day
SARs, weighted average remaining contractual term, exercisable	4 years 3 months 21 days
SARs, aggregate intrinsic value | $	$ 424
SARs, aggregate intrinsic value, vested and expected to vest | $	421
SARs, aggregate intrinsic value, exercisable | $	$ 403

Share-Based Compensation Summar

Share-Based Compensation Summary of SARs Exercised (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Total intrinsic value of SARs exercised	$ 102	$ 212	$ 260
Total fair value of SARs vested	$ 39	$ 46	$ 66

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Performance-Based Restricted Stock Units Outstanding (Detail) - $ / shares shares in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Percentage of Target Payout on which Performance Based Time-vested Restricted Stock Units are Based	100.00%
Expected forfeited performance-based restricted stock units (shares)	63
Units In Excess Of Expected Performance Payout	555
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	962
Granted, sock units (shares)	406
Distributed, stock units (shares)	(39)
Forfeited, canceled or expired, stock units (shares)	(373)
Stock units, ending balance (shares)	957	962
Stock units, vested and expected to vest at ending balance (shares)	339
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock units exercise price, beginning balance (USD per share)	$ 244.42
Granted, stock units weighted average grant date fair value (USD per share)	216.39	$ 245.06	$ 237.55
Distributed, stock units exercise price (USD per share)	252.57
Forfeited, canceled or expired, stock units exercise price (USD per share)	245.86
Stock units exercise price, ending balance (USD per share)	231.63	$ 244.42
Stock units, vested and expected to vest at ending balance, exercise price (USD per share)	$ 227.92
Time-Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	1,697
Granted, sock units (shares)	881
Distributed, stock units (shares)	(601)
Forfeited, canceled or expired, stock units (shares)	(421)
Stock units, ending balance (shares)	1,556	1,697
Stock units, vested and expected to vest at ending balance (shares)	1,478
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock units exercise price, beginning balance (USD per share)	$ 226.01
Granted, stock units weighted average grant date fair value (USD per share)	223.60	$ 249.94	$ 235.50
Distributed, stock units exercise price (USD per share)	231.44
Forfeited, canceled or expired, stock units exercise price (USD per share)	231.29
Stock units exercise price, ending balance (USD per share)	221.11	$ 226.01
Stock units, vested and expected to vest at ending balance, exercise price (USD per share)	$ 220.60

Share-Based Compensation Weight

Share-Based Compensation Weighted Average Grant Date Fair Value of Restricted Stock Units (Details) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Performance-Based Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (USD per share)	$ 216.39	$ 245.06	$ 237.55
Time-Vested Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (USD per share)	$ 223.60	$ 249.94	$ 235.50

Share-Based Compensation Fair V

Share-Based Compensation Fair Value of Stock Units Vested (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Performance-Based Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of restricted stock units	$ 16	$ 27	$ 33
Time-Vested Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of restricted stock units	$ 203	$ 211	$ 254

Benefit Plans - Net Pension and

Benefit Plans - Net Pension and Other Postretirement Cost (Detail) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 150	$ 153	$ 134
Interest cost	71	84	107
Expected return on plan assets	(174)	(188)	(180)
Amortization of prior service credit	(16)	(13)	(13)
Amortization of loss	97	97	78
Curtailment/settlement loss	9	4	10
Net pension cost	137	137	135
Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Net pension cost	$ 41	$ 41	$ 32

Benefit Plans - Additional Info

Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Percent of total assets domestic plans		68.00%
Cost of the savings incentive plan		$ 153	$ 111	$ 126
Fixed Income Funds
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		45.00%
Diversified
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		23.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		32.00%
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		$ 3,222	3,045	2,926
Pension plan projected benefit obligations		3,889	3,953	$ 3,731
Employer contribution		66	42
Foreign Plans | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		1,033	935
Pension plan projected benefit obligations		$ 1,320	1,321
Percent of total plan assets foreign plans		32.00%
Foreign Plans | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		$ 297	335
United States | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		2,189	2,108
Employer contribution		16
United States | Pension Plans | Subsequent Event
Defined Benefit Plan Disclosure [Line Items]
Employer contribution	$ 134
United States | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		686	737
United States | Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Pension plan projected benefit obligations		$ 138	$ 148

Benefit Plans - Change in Benef

Benefit Plans - Change in Benefit Obligation, Change in Fair Value of Plan Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Amounts recognized in the Consolidated Balance Sheets at September 30:
Long-term Employee Benefit Obligations	$ (1,228)	$ (1,435)
Pension Plans
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Beginning obligation	3,953	3,731
Service cost	150	153	$ 134
Interest cost	71	84	107
Plan amendments	30	0
Benefits paid	(156)	(186)
Impact of acquisitions	0	10
Actuarial (gain) loss	(69)	104
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement and Curtailment	49
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement		(17)
Other, includes translation	(19)	(74)
Ending obligation	3,889	3,953	3,731
Change in fair value of plan assets:
Beginning fair value	3,045	2,926
Actual return on plan assets	317	222
Employer contribution	66	42
Benefits paid	(156)	(186)
Impact of acquisitions	0	7
Settlements	(55)	(17)
Other, includes translation	5	51
Ending fair value	3,222	3,045	$ 2,926
Funded Status at September 30:
Unfunded benefit obligation	(667)	(908)
Amounts recognized in the Consolidated Balance Sheets at September 30:
Other	29	16
Salaries, wages and related items	(29)	(23)
Long-term Employee Benefit Obligations	(667)	(901)
Net amount recognized	(667)	(908)
Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30:
Prior service credit	41	31
Net actuarial loss	(972)	(1,281)
Net amount recognized	$ (931)	$ (1,250)

Benefit Plans - Pension Plans w

Benefit Plans - Pension Plans with Accumulated Benefit Obligations (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Retirement Benefits [Abstract]
Accumulated benefit obligation exceeds the fair value of plan assets, accumulated benefit obligation	$ 3,309	$ 3,703
Accumulated benefit obligation exceeds the fair value of plan assets, fair value of plan assets	2,712	2,936
Projected benefit obligation exceeds the fair value of plan assets, projected benefit obligation	3,475	3,920
Projected benefit obligation exceeds the fair value of plan assets, fair value of plan assets	$ 2,780	$ 2,996

Benefit Plans - Weighted Averag

Benefit Plans - Weighted Average Assumptions Determining Pension Plan (Detail) - Pension Plans	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Foreign Plans
Net Cost
Discount rate	1.44%	1.39%	2.30%
Expected return on plan assets	4.92%	5.05%	4.98%
Rate of compensation increase	2.20%	2.35%	2.36%
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	1.95%	1.97%	1.84%
Benefit Obligation
Discount rate	1.75%	1.44%	1.39%
Rate of compensation increase	2.63%	2.20%	2.35%
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	2.02%	1.95%	1.97%
United States
Net Cost
Discount rate	2.80%	3.21%	4.26%
Expected return on plan assets	6.25%	7.25%	7.25%
Rate of compensation increase	4.30%	4.29%	4.29%
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	4.00%	4.00%	4.00%
Benefit Obligation
Discount rate	2.89%	2.80%	3.21%
Rate of compensation increase	4.31%	4.30%	4.29%
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	4.00%	4.00%	4.00%

Benefit Plans - Expected Benefi

Benefit Plans - Expected Benefit Payments (Detail) - Pension Plans $ in Millions	Sep. 30, 2021USD ($)
Defined Benefit Plan Disclosure [Line Items]
2022	$ 242
2023	174
2024	178
2025	189
2026	206
2027-2031	$ 1,113

Benefit Plans - Fair Value Meas

Benefit Plans - Fair Value Measurements of Plan Assets (Detail) - Pension Plans - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 3,222	$ 3,045	$ 2,926
United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,189	2,108
United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	679	656
United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	184	95
United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46	40
United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	141	141
United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	686	737
United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	168	147
United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	286	291
Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,033	935
Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	55	34
Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13	3
Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	264	212
Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	121	102
Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	297	335
Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	12
Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	107	72
Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	44	34
Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	118	131
Net Asset Value | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	195	193
Net Asset Value | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	43	43
Net Asset Value | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	152	151
Net Asset Value | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,405	1,330
Level 1 | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	297	273
Level 1 | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	162	74
Level 1 | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	643	694
Level 1 | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	168	147
Level 1 | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	135	141
Level 1 | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	765	611
Level 1 | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	37	15
Level 1 | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	10	0
Level 1 | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	249	115
Level 1 | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	72	63
Level 1 | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	297	335
Level 1 | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	12
Level 1 | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	84	70
Level 1 | Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	0
Level 1 | Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	590	584
Level 2 | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	382	383
Level 2 | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22	21
Level 2 | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46	40
Level 2 | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	141	141
Level 2 | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	124	183
Level 2 | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18	19
Level 2 | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	3
Level 2 | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	97
Level 2 | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	49	39
Level 2 | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	1
Level 2 | Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31	24
Level 2 | Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	145	141
Level 3 | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	0
Level 3 | Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	11	10
Level 3 | Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 118	$ 131

Divestiture - Additional Inform

Divestiture - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business	$ 0	$ 0	$ 336
Advanced Bioprocessing
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business			$ 336

Business Restructuring Charge_2

Business Restructuring Charges - Changes in Restructuring Balance (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
CR Bard Inc
Restructuring Reserve [Roll Forward]
Beginning balance	$ 16	$ 23	$ 33
Charged to expense	3	49	118
Cash payments	(7)	(32)	(39)
Non-cash settlements	0	(24)	(89)
Other adjustments	1
Ending balance	11	16	23
CR Bard Inc | Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance	15	22	33
Charged to expense	1	7	23
Cash payments	(5)	(14)	(34)
Non-cash settlements	0	0	0
Other adjustments	1
Ending balance	10	15	22
CR Bard Inc | Other
Restructuring Reserve [Roll Forward]
Beginning balance	1	1	0
Charged to expense	2	42	95
Cash payments	(2)	(18)	(5)
Non-cash settlements	0	(24)	(89)
Other adjustments	0
Ending balance	1	1	1
Other Initiatives
Restructuring Reserve [Roll Forward]
Beginning balance	20	34	27
Charged to expense	47	46	62
Cash payments	(55)	(58)	(52)
Non-cash settlements	(4)	(2)	(3)
Other adjustments	0
Ending balance	8	20	34
Other Initiatives | Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance	17	31	23
Charged to expense	13	13	29
Cash payments	(26)	(27)	(21)
Non-cash settlements	0	0	0
Other adjustments	0
Ending balance	4	17	31
Other Initiatives | Other
Restructuring Reserve [Roll Forward]
Beginning balance	3	3	4
Charged to expense	34	33	33
Cash payments	(29)	(31)	(31)
Non-cash settlements	(4)	(2)	(3)
Other adjustments	0
Ending balance	$ 4	$ 3	$ 3

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 20,122	$ 19,748
Accumulated Amortization	(7,385)	(5,981)
Finite-Lived Intangible Assets, Net	12,737	13,767
Unamortized intangible assets	46	46
Acquired in-process research and development
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	44	44
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	2	2
Developed technology
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	14,399	14,105
Accumulated Amortization	(4,983)	(3,959)
Finite-Lived Intangible Assets, Net	9,417	10,146
Customer relationships
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,658	4,616
Accumulated Amortization	(1,839)	(1,509)
Finite-Lived Intangible Assets, Net	2,818	3,107
Product rights
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	123	119
Accumulated Amortization	(83)	(73)
Finite-Lived Intangible Assets, Net	40	46
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	409	408
Accumulated Amortization	(137)	(120)
Finite-Lived Intangible Assets, Net	271	288
Patents and other
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	533	500
Accumulated Amortization	(342)	(320)
Finite-Lived Intangible Assets, Net	$ 191	$ 180

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible amortization expense	$ 1,403	$ 1,384	$ 1,497
Estimated aggregate amortization expense in 2022	1,399
Estimated aggregate amortization expense in 2023	1,386
Estimated aggregate amortization expense in 2024	1,384
Estimated aggregate amortization expense in 2025	1,383
Estimated aggregate amortization expense in 2026	$ 1,357

Intangible Assets - Reconciliat

Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 23,620	$ 23,376
Goodwill, Acquired During Period	264	117
Goodwill, Purchase Accounting Adjustments	6	5
Goodwill, Foreign Currency Translation Gain (Loss)	12	122
Goodwill, ending balance	23,901	23,620
Medical
Goodwill [Roll Forward]
Goodwill, beginning balance	10,044	9,989
Goodwill, Acquired During Period	193	10
Goodwill, Purchase Accounting Adjustments	4	0
Goodwill, Foreign Currency Translation Gain (Loss)	15	44
Goodwill, ending balance	10,255	10,044
Life Sciences
Goodwill [Roll Forward]
Goodwill, beginning balance	837	772
Goodwill, Acquired During Period	0	58
Goodwill, Purchase Accounting Adjustments	0	1
Goodwill, Foreign Currency Translation Gain (Loss)	(1)	7
Goodwill, ending balance	836	837
Interventional
Goodwill [Roll Forward]
Goodwill, beginning balance	12,739	12,615
Goodwill, Acquired During Period	72	49
Goodwill, Purchase Accounting Adjustments	1	4
Goodwill, Foreign Currency Translation Gain (Loss)	(2)	71
Goodwill, ending balance	$ 12,810	$ 12,739

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Reclassification of terminated interest rate swaps to interest expense within the next 12 months	$ (1)
Cash flow hedges	81	$ (67)	$ (6)
Interest rate swaps | Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash flow hedges	72	(75)
Derivative, Notional Amount	1,000	1,500
Commodity forward contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 0	$ 0

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020
Debt | Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 2,543		$ 1,522
Forward exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	2,735		2,519
Currency Swap | Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	1,958		2,971
Commodity forward contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	0		0
Fixed To Floating | Fair Value Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	700		375
Interest rate swaps | Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 1,000		$ 1,500
Derivative, Notional Amount, Terminated		$ 500

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	$ 124	$ (161)	$ (93)
Forward exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	32
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax		(106)	138
Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	(21)
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax		(109)	73
Foreign Exchange Forward
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	0
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax		$ 0	$ (9)
Terminated Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	$ (35)

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurement - Cash and Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Cash and equivalents	$ 2,283	$ 2,825
Restricted Cash and Investments, Current	109	92
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	2,392	2,917	$ 590	$ 1,236
Transfers of financial assets during the period.	$ 1,302	$ 2,163

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Cost of products sold
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset Impairment Charges	$ 49
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	1 year
Life Sciences
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)		$ 57
Medical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset Impairment Charges		$ 41
Interventional
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)			$ 30

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Institutional money market investments	$ 200	$ 1,549
Fair value of debt classified from long term to short term	503	702
Fair value of long-term debt	18,537	18,970
Remaining cash equivalents	$ 2,083	$ 1,276

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Transfers of financial assets during the period.	$ 1,302	$ 2,163
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized	$ 130	$ 256

Debt - Summary of Short-Term De

Debt - Summary of Short-Term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Short-term Debt [Line Items]
Other Short-term Borrowings	$ 0	$ 5
Short-term debt	$ 500	707
Notes 0.174% due June 4, 2021 [Member]
Short-term Debt [Line Items]
Interest rate	0.174%
Current portion of long-term debt	$ 0	701
Floating Rate Notes due June 6, 2022
Short-term Debt [Line Items]
Current portion of long-term debt	$ 500	$ 0

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	3 Months Ended				12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Short-term debt, weighted average interest rate	1.15%		0.20%		1.15%	0.20%
Aggregate annual maturities of long-term debt, 2022	$ 433,000,000				$ 433,000,000
Aggregate annual maturities of long-term debt, 2023	2,749,000,000				2,749,000,000
Aggregate annual maturities of long-term debt, 2024	1,559,000,000				1,559,000,000
Aggregate annual maturities of long-term debt, 2025	2,164,000,000				2,164,000,000
Aggregate annual maturities of long-term debt, 2026	1,053,000,000				1,053,000,000
Debt Instrument, Term						364 days
Letters Of Credit Issuable Under Credit Facility	100,000,000				100,000,000
Swingline Loans Issuable Under Credit Facility	100,000,000				100,000,000
Line Of Credit Facility Maximum Additional Principal Amount Commitments	500,000,000				500,000,000
Line of Credit Facility, Maximum Borrowing Capacity	3,250,000,000				3,250,000,000
Long-term Commercial Paper	0				0
Long-Term Debt	$ 17,110,000,000		$ 17,224,000,000		17,110,000,000	$ 17,224,000,000
Debt Instrument, Repurchase Amount			951,000,000			951,000,000
Extinguishment of Debt, Gain (Loss), Net of Tax			1,000,000		$ 178,000,000	8,000,000	$ 59,000,000
Notes 2.894% due June 6, 2022
Debt Instrument [Line Items]
Interest rate	2.894%				2.894%
Debt Instrument, Repurchased Face Amount	$ 1,535,000,000	$ 265,000,000			$ 1,535,000,000
Debt Instrument, Repurchase Amount	1,566,000,000	275,000,000			$ 1,566,000,000
Extinguishment of Debt, Gain (Loss), Net of Tax	$ 32,000,000	$ 10,000,000
3.300% Notes due March 1, 2023
Debt Instrument [Line Items]
Interest rate	3.30%				3.30%
Debt Instrument, Repurchased Face Amount	$ 294,000,000				$ 294,000,000
Long-Term Debt	0		295,000,000		0	295,000,000
Debt Instrument, Repurchase Amount	307,000,000				$ 307,000,000
Extinguishment of Debt, Gain (Loss), Net of Tax	12,000,000
Revolving Credit Facility due December 29, 2022
Debt Instrument [Line Items]
Debt Instrument, Term					5 years
Borrowings under credit facility	0		$ 0		$ 0	$ 0
Revolving Credit Facility due December 29, 2022 | Maximum
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity	$ 2,750,000,000				$ 2,750,000,000
Term Loan Facility
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity				$ 2,000,000,000
Repayments of Lines of Credit				$ 1,900,000,000

Debt - Summary of Long-Term Deb

Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Long-Term Debt	$ 17,110	$ 17,224
3.125% Notes due November 8, 2021
Debt Instrument [Line Items]
Long-Term Debt	0	1,008
2.894% Notes due June 6, 2022
Debt Instrument [Line Items]
Long-Term Debt	0	1,797
Floating Rate Notes due June 6, 2022
Debt Instrument [Line Items]
Long-Term Debt	$ 0	499
1.000% Notes due December 15, 2022
Debt Instrument [Line Items]
Interest rate	1.00%
Long-Term Debt	$ 579	584
3.300% Notes due March 1, 2023
Debt Instrument [Line Items]
Interest rate	3.30%
Long-Term Debt	$ 0	295
1.401% Notes due May 24, 2023
Debt Instrument [Line Items]
Interest rate	1.401%
Long-Term Debt	$ 347	350
0.632% Notes due June 4, 2023
Debt Instrument [Line Items]
Interest rate	0.632%
Long-Term Debt	$ 926	933
Notes 0.000% due August 13, 2023 [Member]
Debt Instrument [Line Items]
Interest rate	0.00%
Long-Term Debt	$ 463	0
3.875% Notes due May 15, 2024
Debt Instrument [Line Items]
Interest rate	3.875%
Long-Term Debt	$ 146	180
3.363% Notes due June 6, 2024
Debt Instrument [Line Items]
Interest rate	3.363%
Long-Term Debt	$ 994	1,742
3.734% Notes due December 15, 2024
Debt Instrument [Line Items]
Interest rate	3.734%
Long-Term Debt	$ 873	1,370
3.020% Notes due May 24, 2025
Debt Instrument [Line Items]
Interest rate	3.02%
Long-Term Debt	$ 336	320
Notes 0.034% due August 13, 2025 [Member]
Debt Instrument [Line Items]
Interest rate	0.034%
Long-Term Debt	$ 577	0
1.208% Notes due June 4, 2026
Debt Instrument [Line Items]
Interest rate	1.208%
Long-Term Debt	$ 693	699
6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Interest rate	6.70%
Long-Term Debt	$ 168	172
1.900% Notes due December 15, 2026
Debt Instrument [Line Items]
Interest rate	1.90%
Long-Term Debt	$ 577	582
3.700% Notes due June 6, 2027
Debt Instrument [Line Items]
Interest rate	3.70%
Long-Term Debt	$ 1,716	1,715
7.000% Debentures due August 1, 2027
Debt Instrument [Line Items]
Interest rate	7.00%
Long-Term Debt	$ 174	175
6.700% Debentures due August 1, 2028
Debt Instrument [Line Items]
Interest rate	6.70%
Long-Term Debt	$ 173	174
Notes 0.334% due August 13, 2028
Debt Instrument [Line Items]
Interest rate	0.334%
Long-Term Debt	$ 1,037	0
Notes 2.823% due May 20, 2030
Debt Instrument [Line Items]
Interest rate	2.823%
Long-Term Debt	$ 744	743
Notes 1.957% due February 11, 2031
Debt Instrument [Line Items]
Interest rate	1.957%
Long-Term Debt	$ 992	0
Notes 1.213% due February 12, 2036 [Member]
Debt Instrument [Line Items]
Interest rate	1.213%
Long-Term Debt	$ 690	0
6.000% Notes due May 15, 2039
Debt Instrument [Line Items]
Interest rate	6.00%
Long-Term Debt	$ 246	246
5.000% Notes due November 12, 2040
Debt Instrument [Line Items]
Interest rate	5.00%
Long-Term Debt	$ 124	124
Notes 1.336 due August 13, 2041
Debt Instrument [Line Items]
Interest rate	1.336%
Long-Term Debt	$ 1,034	0
4.875% Notes due May 15, 2044
Debt Instrument [Line Items]
Interest rate	4.875%
Long-Term Debt	$ 246	247
4.685% Notes due December 15, 2044
Debt Instrument [Line Items]
Interest rate	4.685%
Long-Term Debt	$ 1,033	1,044
4.669% Notes due June 6, 2047
Debt Instrument [Line Items]
Interest rate	4.669%
Long-Term Debt	$ 1,481	1,485
Notes 3.794% due May 20, 2050
Debt Instrument [Line Items]
Interest rate	3.794%
Long-Term Debt	$ 742	$ 742

Debt - Schedule of Debt Issuanc

Debt - Schedule of Debt Issuances (Details) € in Millions	Sep. 30, 2021USD ($)	Sep. 30, 2021EUR (€)	Mar. 31, 2021USD ($)	Mar. 31, 2021EUR (€)	Jun. 30, 2020USD ($)
Notes 1.957% due February 11, 2031
Debt Instrument [Line Items]
Interest rate	1.957%	1.957%
Debt instrument, face amount			$ 1,000,000,000
Notes 3.125% due November 8, 2021
Debt Instrument [Line Items]
Interest rate	3.125%	3.125%
Notes 2.823% due May 20, 2030
Debt Instrument [Line Items]
Interest rate	2.823%	2.823%
Debt instrument, face amount					$ 750,000,000
Notes 2.404% due June 5, 2020 [Member]
Debt Instrument [Line Items]
Interest rate	2.404%	2.404%
Notes 3.250% due November 12, 2020 [Member]
Debt Instrument [Line Items]
Interest rate	3.25%	3.25%
Notes 3.794% due May 20, 2050
Debt Instrument [Line Items]
Interest rate	3.794%	3.794%
Debt instrument, face amount					$ 750,000,000
Notes 0.000% due August 13, 2023 [Member]
Debt Instrument [Line Items]
Interest rate	0.00%	0.00%
Notes 0.000% due August 13, 2023 [Member] | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €		€ 400
Notes 0.000% due August 13, 2023 [Member] | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount	$ 470,000,000
Notes 0.034% due August 13, 2025 [Member]
Debt Instrument [Line Items]
Interest rate	0.034%	0.034%
Notes 0.034% due August 13, 2025 [Member] | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €		€ 500
Notes 0.034% due August 13, 2025 [Member] | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount	$ 587,000,000
Notes 0.334% due August 13, 2028
Debt Instrument [Line Items]
Interest rate	0.334%	0.334%
Notes 0.334% due August 13, 2028 | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €		€ 900
Notes 0.334% due August 13, 2028 | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,055,000,000
Notes 1.336 due August 13, 2041
Debt Instrument [Line Items]
Interest rate	1.336%	1.336%
Notes 1.336 due August 13, 2041 | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €		€ 900
Notes 1.336 due August 13, 2041 | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,055,000,000
Notes 1.213% due February 12, 2036 [Member]
Debt Instrument [Line Items]
Interest rate	1.213%	1.213%
Notes 1.213% due February 12, 2036 [Member] | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €				€ 600
Notes 1.213% due February 12, 2036 [Member] | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount			$ 728,000,000
Notes 0.174% due June 4, 2021 [Member]
Debt Instrument [Line Items]
Interest rate	0.174%	0.174%

Debt - Extinguishments of Debt

Debt - Extinguishments of Debt (Details) € in Millions, $ in Millions	3 Months Ended					12 Months Ended
	Sep. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Mar. 31, 2021EUR (€)
Extinguishment of Debt [Line Items]
Long-Term Debt	$ 17,110			$ 17,224		$ 17,110	$ 17,224
Debt Instrument, Repurchase Amount				951			951
Losses on debt extinguishment				(1)		(178)	(8)	$ (59)
Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt				950			950
Notes 2.894% due June 6, 2022
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount	$ 1,535		$ 265			$ 1,535
Interest rate	2.894%					2.894%
Debt Instrument, Repurchase Amount	$ 1,566		275			$ 1,566
Losses on debt extinguishment	(32)		(10)
Notes 2.894% due June 6, 2022 | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt	1,534		$ 265			1,534
3.300% Notes due March 1, 2023
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount	$ 294					$ 294
Interest rate	3.30%					3.30%
Long-Term Debt	$ 0			295		$ 0	295
Debt Instrument, Repurchase Amount	307					307
Losses on debt extinguishment	(12)
3.300% Notes due March 1, 2023 | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt	295					295
Notes 3.875% due May 15, 2024
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount	33					33
Debt Instrument, Repurchase Amount	35					35
Losses on debt extinguishment	(2)
Notes 3.875% due May 15, 2024 | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt	33					33
3.734% Notes due December 15, 2024
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount	$ 500					$ 500
Interest rate	3.734%					3.734%
Long-Term Debt	$ 873			1,370		$ 873	1,370
Debt Instrument, Repurchase Amount	546					546
Losses on debt extinguishment	(48)
3.734% Notes due December 15, 2024 | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt	499					499
3.363% Notes due June 6, 2024
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount	$ 752					$ 752
Interest rate	3.363%					3.363%
Long-Term Debt	$ 994			1,742		$ 994	1,742
Debt Instrument, Repurchase Amount	808					808
Losses on debt extinguishment	(58)
3.363% Notes due June 6, 2024 | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt	$ 750					$ 750
Notes 3.125% due November 8, 2021
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount		$ 1,000
Interest rate	3.125%					3.125%
Debt Instrument, Repurchase Amount		1,019
Losses on debt extinguishment		(14)
Notes 3.125% due November 8, 2021 | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt		1,005
Notes 0.174% due June 4, 2021 [Member]
Extinguishment of Debt [Line Items]
Interest rate	0.174%					0.174%
Debt Instrument, Repurchase Amount		730
Losses on debt extinguishment		(1)
Notes 0.174% due June 4, 2021 [Member] | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt		728
Notes 0.174% due June 4, 2021 [Member] | Euro Member Countries, Euro
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount | €									€ 600
Notes 0.174% due June 4, 2021 [Member] | United States of America, Dollars
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount		$ 728
Notes 2.404% due June 5, 2020 [Member]
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount					$ 1,000
Interest rate	2.404%					2.404%
Losses on debt extinguishment					0
Notes 2.404% due June 5, 2020 [Member] | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt					1,000
Notes 3.250% due November 12, 2020 [Member]
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount				200	500		200
Interest rate	3.25%					3.25%
Debt Instrument, Repurchase Amount					506
Losses on debt extinguishment					(6)
Notes 3.250% due November 12, 2020 [Member] | Long-term Debt
Extinguishment of Debt [Line Items]
Long-Term Debt					$ 500
Floating Rate Notes Due December 29, 2020
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount				$ 750			$ 750

Debt - Summary of Interest Cost

Debt - Summary of Interest Costs and Payments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Debt Disclosure [Abstract]
Charged to operations	$ 469	$ 528	$ 639
Capitalized	44	43	44
Total interest costs	512	571	683
Interest paid, net of amounts capitalized	$ 474	$ 515	$ 658

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes from Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Federal	$ 102	$ (50)	$ 235
State and local, including Puerto Rico	46	47	41
Foreign	290	400	300
Total, Current	438	397	576
Domestic	(286)	(184)	(577)
Foreign	(2)	(101)	(56)
Total, Deferred	(288)	(286)	(633)
Income tax provision	150	111	(57)
Unrecognized tax benefits interest and penalties reflected in current year	$ 5	$ 1	$ 26

Income Taxes - Components of In

Income Taxes - Components of Income from Continuing Operations Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Domestic, including Puerto Rico	$ 133	$ (489)	$ 799
Foreign	2,109	1,474	377
Income Before Income Taxes	$ 2,242	$ 985	$ 1,176

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Jun. 30, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Income Tax [Line Items]
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNew				21.00%
Federal statutory tax rate		21.00%	21.00%	21.00%	35.00%
Tax Cuts and Jobs Act, Income Tax Expense (Benefit)				$ 50
OtherTaxExpenseBenefitRelatedtoHistoricUnremittedForeignEarnings	$ 67	$ 138
Deferred Income Taxes and Other
Income Tax [Line Items]
Indemnification liability, non-current		$ 119

Income Taxes - Summary of Gross

Income Taxes - Summary of Gross Amounts of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at October 1	$ 620	$ 577	$ 601
Increase due to acquisitions	2	1	3
Increase due to current year tax positions	23	35	11
Increase due to prior year tax positions	6	76	6
Decreases due to prior year tax positions	(4)	(49)	(39)
Decrease due to settlements with tax authorities	(183)	(4)	0
Decrease due to lapse of statute of limitations	(100)	(16)	(5)
Balance at September 30	364	620	577
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 447	$ 719	$ 624

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Compensation and benefits, assets	$ 527	$ 554
Loss and credit carryforwards, assets	2,107	1,900
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves	191	241
Other, assets	555	501
Deferred income taxes, assets, gross	3,379	3,196
Valuation allowance, assets	(2,036)	(1,820)
Deferred income taxes, assets	1,343	1,376
Property and equipment, liabilities	410	361
Deferred Tax Liabilities, Other Finite-Lived Assets	2,160	2,408
Other, liabilities	123	137
Deferred income taxes, liabilities, gross	2,693	2,906
Deferred income taxes, liabilities	$ 2,693	$ 2,906

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate (Detail)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21.00%	21.00%	21.00%	35.00%
U.S. tax legislation (see discussion above)	0	0	(0.043)
State and local income taxes, net of federal tax benefit	(1.90%)	(1.90%)	0.10%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	(8.10%)	(14.80%)	(6.60%)
Effect of foreign operations	(0.10%)	19.10%	(5.50%)
Effect of Research Credits and FDII/Domestic Production Activities	(1.60%)	(5.00%)	(3.30%)
Effect of share-based compensation	0.10%	(4.50%)	(3.90%)
Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent	0.00%	(4.50%)	(2.00%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	(1.70%)	0.00%	0.00%
Other, net	(1.00%)	1.90%	(0.30%)
Total	6.70%	11.30%	(4.80%)

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Holiday (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Tax reductions related to tax holidays	$ 248	$ 136	$ (43)
Income Tax Holiday, Income Tax Benefits Per Share	$ 0.85	$ 0.48	$ (0.16)
Income taxes paid, net	$ 670	$ 518	$ 536

Leases, Codification Topic 84_3

Leases, Codification Topic 842 (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Lessee, Lease, Description [Line Items]
Operating Lease, Weighted Average Remaining Lease Term	6 years 10 months 24 days
Operating Lease, Weighted Average Discount Rate, Percent	2.20%
Operating Lease, Cost	$ 132	$ 131
Rental expense for operating leases			$ 169
Gross Proceeds from Sale Leaseback Transaction	225
Other Operating Income (Expense)
Lessee, Lease, Description [Line Items]
Sale and Leaseback Transaction, Gain (Loss), Net	$ 158
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Lessee, Operating Lease, Renewal Term	6 months
Minimum | Sale Leaseback Transaction, Term of Contract
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	2 years
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	25 years
Lessee, Operating Lease, Renewal Term	12 months
Maximum | Sale Leaseback Transaction, Term of Contract
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	3 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets	Other Assets
Right-of-use assets recorded in Other Assets	$ 446	$ 418
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Current lease liabilities recorded in Payables, accrued expenses and other current liabilities	$ 126	$ 106
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Deferred Income Taxes and Other Liabilities	Deferred Income Taxes and Other Liabilities
Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities	$ 344	$ 336

Leases - Lessee, Operating Leas

Leases - Lessee, Operating Lease, Liability, Maturity (Details) $ in Millions	Sep. 30, 2021USD ($)
Leases [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 134
Lessee, Operating Lease, Liability, to be Paid, Year Two	96
Lessee, Operating Lease, Liability, to be Paid, Year Three	63
Lessee, Operating Lease, Liability, to be Paid, Year Four	45
Lessee, Operating Lease, Liability, to be Paid, Year Five	37
Lessee, Operating Lease, Liability, to be Paid, after Year Five	140
Lessee, Operating Lease, Liability, to be Paid	515
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	45
Accrued Expenses and Deferred Income Taxes and Other Liabilities
Leases [Abstract]
Operating Lease, Liability	470
Lessee, Lease, Description [Line Items]
Operating Lease, Liability	$ 470

Supplemental Financial Inform_3

Supplemental Financial Information - Other Income (Expense), Net (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Equity Securities, FV-NI, Unrealized Gain (Loss)		$ 57	$ 13	$ 18
Foreign Currency Transaction Gain (Loss), Realized		(13)	(17)	(23)
Losses on debt extinguishment	$ (1)	(178)	(8)	(59)
Royalty Income, Nonoperating		0	17	64
Insurance Recoveries		0	0	35
Other Nonoperating Income		(3)	(3)	4
Other Nonoperating Income (Expense)		(97)	23	43
Other Nonoperating Income (Expense)
Deferred Compensation Investment Income (Expense)		43	24	6
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)		(1)	7	(2)
Gains (Losses) on Product Related Matters		$ (2)	$ (9)	$ 0

Supplemental Financial Inform_4

Supplemental Financial Information - Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 94	$ 88	$ 86
Additions charged to costs and expenses	118	78	125
Deductions and other	(114)	(73)	(123)
Ending Balance	97	94	88
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	80	75	75
Additions charged to costs and expenses	18	40	31
Deductions and other	(22)	(35)	(31)
Ending Balance	76	80	75
Allowance for Cash Discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	14	13	12
Additions charged to costs and expenses	99	39	94
Deductions and other	(92)	(38)	(92)
Ending Balance	$ 21	$ 14	$ 13

Supplemental Financial Inform_5

Supplemental Financial Information - Inventories (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Materials	$ 641	$ 602
Work in process	402	335
Finished products	1,823	1,806
Inventories	$ 2,866	$ 2,743

Supplemental Financial Inform_6

Supplemental Financial Information - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Land	$ 137	$ 166
Buildings	3,264	3,082
Machinery, equipment and fixtures	9,301	8,454
Leasehold improvements	241	216
Property, Plant and Equipment, gross	12,942	11,919
Less accumulated depreciation and amortization	6,549	5,996
Property, Plant and Equipment, Net	$ 6,393	$ 5,923